Autosomal Dominant Nonsyndromic Hearing Loss 2B

Mendelian MONDO:0012976 Pathograph 9 Show in embeddings browser Autosomal Dominant Nonsyndromic Hearing Loss Hereditary Hearing Loss

DFNA2B denotes the proposed association between heterozygous GJB3 variants and autosomal dominant nonsyndromic hearing loss. The founding report described two families with bilateral high-frequency impairment. ClinGen classified the relationship Disputed in 2018; this classification remained listed when checked in September 2026. It reflects insufficient or contradictory evidence, not proof that every GJB3 allele is harmless. Case-control studies did not find significant enrichment of the frequently screened p.Arg180* allele, but their variant selection and age distributions limit generalization. Selected connexin 31 variants show trafficking, cellular-stress or coupling abnormalities in expression systems, whereas surviving homozygous null mice have normal inner-ear morphology and function. These findings do not establish a human deafness mechanism. The separately curated GJB3-erythrokeratodermia variabilis relationship is Definitive. Hearing assessment, genetic evaluation and rehabilitation remain appropriate for the observed phenotype while its cause is unresolved.

Ask OpenScientist

Ask a research question about Autosomal Dominant Nonsyndromic Hearing Loss 2B. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
2
Phenotypes
1
Hypotheses
2
Gaps
9
Pathograph
1
Genes
5
Medical Actions
3
Differentials
1
Trials
1
Models
18
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant HP:0000006
Autosomal dominant inheritance is the proposed historical model, not a confirmed recurrence-risk model for a GJB3 finding. Absence of reported family history in all 23 p.Arg180* carriers in one cohort supplies no segregation support, but does not logically exclude dominant inheritance: family ascertainment, age-dependent penetrance or de novo occurrence can affect pedigrees. A 50% chance of transmitting a heterozygous allele must not be presented as a 50% chance of GJB3-related hearing loss while pathogenicity is unresolved.
Autosomal dominant inheritance
Show evidence (3 references)
PMID:9843210 SUPPORT Human Clinical
"Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were associated with high-frequency hearing loss in two families."
The family-based observation underlying the dominant claim.
PMID:29106878 SUPPORT PRIMARY RESULT Human Clinical
"All 23 patients were sporadic cases and had no family history of deafness."
Documents absence of reported family history; it is not direct refutation of dominant inheritance.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"It is appropriate to offer genetic counseling (including discussion of the probability of hearing loss in offspring and reproductive options) to young adults who have hearing loss."
General counseling recommendation; a disputed GJB3 attribution cannot supply a validated disease recurrence risk.
◈

Mechanistic Hypotheses

1
Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
cx31_gap_junction_deafness ALTERNATIVE
Evidence balance 1 support 1 refute
Selected GJB3 variants alter connexin 31 localization, induce cellular stress or reduce coupling in transfected cells. These effects provide a candidate molecular basis for the disputed auditory association, but neither expression in auditory tissue nor abnormal heterozygous coexpression proves clinical pathogenicity or a dominant-negative mechanism. Dominant disease could involve dosage reduction, dominant interference or toxic gain of function. The normal hearing of surviving Gjb3-null mice challenges a simple loss-of-function model but does not test a heterozygous toxic missense allele. The cited evidence does not establish the proposed cellular-to-human auditory chain.
Pathograph links
Heterozygous GJB3 Variant -> Connexin 31 Intracellular Trafficking Abnormality DIRECT Two hearing-loss-associated variants have been shown to do this directly in transfected cells.
Heterozygous GJB3 Variant -> Connexin 31-Associated Endoplasmic Reticulum Stress DIRECT Selected mutant constructs induced BiP responses in transfected cells.
Heterozygous GJB3 Variant -> V174M-Associated Interference with Connexin 26 Trafficking DIRECT V174M-specific coexpression result; not a property assigned to all GJB3 alleles.
Connexin 31 Intracellular Trafficking Abnormality -> Reduced Connexin 31-Mediated Coupling in Expression Systems INDIRECT UNKNOWN INTERMEDIATES Trafficking abnormalities and deficient coupling co-occur in mutant expression systems. The cited experiments do not isolate localization from every other effect of the variants.
Reduced Connexin 31-Mediated Coupling in Expression Systems -> Reported Sensorineural Hearing Loss INDIRECT UNKNOWN INTERMEDIATES This proposed bridge from cell-culture coupling defects to human hearing loss remains unestablished. Normal hearing in null mice limits a simple loss-of-function explanation.
Show evidence (2 references)
PMID:21204020 SUPPORT In Vitro
"Together, the HI-associated C×31 mutants are impaired in trafficking, promote ER stress, and hence lose the ability to assemble functional gap junctions."
The molecular half of the hypothesis, measured in transfected cells.
PMID:11237463 REFUTE INDIRECT Model Organism
"No morphological or functional defects of skin or inner ear were observed in surviving adult Gjb3(-/-) mice."
Normal inner-ear function in surviving null mice challenges simple loss of function. Species, genotype and survivor selection limit extrapolation to heterozygous human alleles. Normal null skin does not test the diverse dominant mechanisms reported for EKV.
?

Discussions and Knowledge Gaps

2
Does a heterozygous trafficking-defective GJB3 allele cause hearing loss in any organism?
KNOWLEDGE GAP OPEN gap_gjb3_dominant_negative_untested_in_vivo
Attached to
genetic#GJB3 mechanistic_hypotheses#cx31_gap_junction_deafness
The cited cell studies measure selected variant effects, while the cited in-vivo study tests a homozygous null. Heterozygous knock-in studies with age-appropriate auditory measurements could test variant-specific effects, but positive hearing loss alone would not distinguish dominant interference from toxic gain of function. Negative results for one allele or model would not resolve every human GJB3 association.
Proposed experiments
Auditory phenotyping of mice heterozygous for a human DFNA2B GJB3 allele
gjb3_knockin_heterozygote_auditory_phenotype
Compare heterozygous R180X or E183K knock-in mice with wild-type, heterozygous-null and homozygous-null controls across age and frequency. Measure auditory function and variant expression, connexin localization and coupling. Use coexpression and rescue experiments to distinguish interference with wild-type protein from other toxic effects.
Would support
mechanistic_hypotheses#cx31_gap_junction_deafness
Supporting outcome
  • A reproducible auditory phenotype linked to a specific knock-in would support that allele's in-vivo effect. Dominant-negative attribution would additionally require evidence of interference with wild-type function.
Refuting outcome
  • Normal hearing with verified expression and adequate observation would weaken that allele-specific mouse mechanism, without proving absence of human disease or justifying retirement of all DFNA2B associations.
How do genotype, species and compensation limit interpretation of normal hearing in the Gjb3-null mouse?
HUMAN MODEL MISMATCH OPEN mismatch_gjb3_null_mouse_normal_in_skin_too
Attached to
animal_models#Cx31-deficient (Gjb3 lacZ knock-in) mouse
The null study reports normal adult skin and inner ear, but dominant EKV variants have diverse cellular effects. A null does not test every dominant variant mechanism in either organ. Proposed compensation and species differences require direct study; neither normal skin nor an EKV knock-in result automatically validates or invalidates an auditory model.
Proposed experiments
Reassessment of the Gjb3-null mouse against the established skin phenotype
gjb3_null_mouse_skin_and_ear_reassessment
Compare null and selected disease-variant genotypes with matched controls using skin and auditory assays, expression measurements and connexin localization. Test candidate compensation directly instead of assuming that a shared lack of phenotype establishes it.
Would support
animal_models#Cx31-deficient (Gjb3 lacZ knock-in) mouse
Supporting outcome
  • Reproducible genotype-specific differences would define which mechanisms and tissues the models capture; a skin phenotype would not independently establish auditory-model sensitivity.
Refuting outcome
  • Failure to reproduce a selected phenotype would identify a limitation of that genotype and assay, not prove that all mouse Gjb3 models are uninformative.
⚙

Pathophysiology

6
Heterozygous GJB3 Variant
The founding report associated heterozygous missense and nonsense GJB3 variants with hearing loss in two families. GJB3 encodes connexin 31. Selected variants have measurable effects in expression systems, but clinical pathogenicity and penetrance remain disputed; heterozygosity alone does not establish causation or select among dosage, dominant-negative and toxic gain-of-function mechanisms. The frequently screened c.538C>T (p.Arg180*) allele lacked significant enrichment in subsequent case-control studies.
Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
Genetic context GJB3 hgnc:4285 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns GJB3 (hgnc:4285). hgnc:4285 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: HETEROZYGOUS
Heterozygous in the reported families. functional_impact_category is omitted deliberately: the trafficking data show the mutant protein is made and mislocalised rather than absent, and whether that constitutes loss of function or a dominant negative is the open question rather than something the entry can assert.
Downstream
Connexin 31 Intracellular Trafficking Abnormality Two hearing-loss-associated variants have been shown to do this directly in transfected cells. Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
Connexin 31-Associated Endoplasmic Reticulum Stress Selected mutant constructs induced BiP responses in transfected cells. Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
V174M-Associated Interference with Connexin 26 Trafficking V174M-specific coexpression result; not a property assigned to all GJB3 alleles. Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
Show evidence (2 references)
PMID:9843210 SUPPORT Human Clinical
"Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were associated with high-frequency hearing loss in two families."
The founding association, on two families.
PMID:29106878 REFUTE Human Clinical
"Our results showed that the GJB3 c.538C>T variant has a very low incidence in the Chinese population, and there was no clear evidence to support a role of the GJB3 c.538C>T variant in the autosomal dominant form of non-syndromic deafness."
The authors found no clear support for this particular allele as a dominant cause; this does not establish a result for every GJB3 variant.
Connexin 31 Intracellular Trafficking Abnormality
R180X accumulated primarily in the endoplasmic reticulum and E183K in Golgi-like punctate structures in transfected cells. V174M accumulated in lysosomes in HeLa cells. Intracellular localization therefore differs by variant and is not uniformly ER retention. These findings concern selected expression constructs, not demonstrated human cochlear lesions. EKV-associated variants have diverse cellular effects and should not all be assigned this same mechanism.
Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
Downstream
Reduced Connexin 31-Mediated Coupling in Expression Systems Trafficking abnormalities and deficient coupling co-occur in mutant expression systems. The cited experiments do not isolate localization from every other effect of the variants. Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
Show evidence (3 references)
PMID:21204020 SUPPORT In Vitro
"In contrast, two HI-associated C×31 mutants, C×31R180X and C×31E183K resided primarily in the ER and Golgi-like intracellular punctate structures, respectively, and failed to mediate lucifer yellow transfer."
The retention and dye-transfer failure, in transfected cells.
PMID:21204020 SUPPORT In Vitro
"In transfected cells, wild type C×31 protein (C×31wt) forms functional gap junction at cell-cell-contacts."
The wild-type control that makes the mutant result interpretable.
PMID:24913888 SUPPORT DIRECT PRIMARY RESULT In Vitro
"Conversely, the p.V174M missense mutation resulted in the accumulation of the mutant protein in the lysosomes rather than in the cytoplasmic membrane."
Variant-specific lysosomal accumulation in HeLa cells; the clinical gene-disease relationship remains disputed.
Connexin 31-Associated Endoplasmic Reticulum Stress
Expression of R180X and E183K increased the ER chaperone BiP and its association with connexin 31. This is a cellular stress response in transfected cells; its contribution to human hearing loss has not been established.
Show evidence (1 reference)
PMID:21204020 SUPPORT DIRECT PRIMARY RESULT In Vitro
"Expression of C×31 mutants but not C×31wt leads to upregulation of and increased association with the ER chaperone BiP indicating ER stress induction."
BiP response and association support ER stress in the expression system.
V174M-Associated Interference with Connexin 26 Trafficking
In HeLa coexpression experiments, V174M interfered with wild-type Cx26 trafficking and membrane targeting but did not alter wild-type Cx31 trafficking. The authors proposed trans-dominant-negative interference; this is not equivalent to demonstrated dominant-negative inhibition of Cx31 or proof of deafness in carriers.
Show evidence (1 reference)
PMID:24913888 SUPPORT DIRECT PRIMARY RESULT In Vitro
"CX31V174M co-expressed with either CX31WT or CX26WT studies, suggested the impairment of the ability of CX26WT proteins to intracellular trafficking and targeting to the plasma membrane, but did not influence the trafficking of CX31WT."
Differential effect on two wild-type connexins in the coexpression system.
Reduced Connexin 31-Mediated Coupling in Expression Systems
Selected mutants reduce intercellular dye transfer or ionic coupling in heterologous expression systems. V27M and V84I did not function normally when coexpressed with wild-type Cx31; this does not independently establish dominant-negative action or clinical pathogenicity. V174M did not form functional dye-transferring channels and interfered with Cx26 trafficking while sparing Cx31 wild-type trafficking. Mouse localization and rat transcript data support auditory expression, not direct demonstration of gap-junction coupling between inner hair cells or spiral ganglion neurons.
Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
connexin 31 gap junction channel activity GO:0005243 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased connexin 31 gap junction channel activity, annotated with gap junction channel activity (GO:0005243). GO:0005243 is a molecular function from the Gene Ontology.
Downstream
Reported Sensorineural Hearing Loss This proposed bridge from cell-culture coupling defects to human hearing loss remains unestablished. Normal hearing in null mice limits a simple loss-of-function explanation. Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes dominant high-frequency hearing loss
Show evidence (4 references)
PMID:21204020 SUPPORT INDIRECT PRIMARY RESULT Model Organism
"we show that expression of C×31 in the mouse inner ear is developmentally regulated with a high level in adult inner hair cells and spiral ganglion neurons that are critical for the hearing process."
Auditory expression in mouse tissue provides context; it does not demonstrate functional coupling between these cell types.
PMID:22617145 SUPPORT In Vitro
"The results of biochemical and ionic coupling tests showed that both the Cx31-p.V27M and Cx31-p.V84I variants did not function normally when each was expressed as a heterozygote with the wild-type Cx31."
Abnormal biochemical and ionic coupling under coexpression; not a sufficient demonstration of dominant-negative interference or human causality.
PMID:9843210 SUPPORT INDIRECT Model Organism
"Moreover, expression of Gjb3 was identified in rat inner ear tissue by RT-PCR."
Expression in the inner ear, graded INDIRECT because presence of a transcript is consistent with a role and does not establish one.
+ 1 more reference
Reported Sensorineural Hearing Loss
Bilateral high-frequency hearing loss was reported in the two founding families. Progressive or later-onset descriptions in reviews are not a validated natural-history series for a molecularly confirmed DFNA2B cohort. The clinical observations can be recorded without accepting the disputed attribution to GJB3.
Animal models
Cx31-deficient (Gjb3 lacZ knock-in) mouse Mouse fails to recapitulate Surviving adult null mice did not reproduce the auditory endpoint. The study did not directly measure the cell-culture coupling event represented elsewhere in this entry.
Downstream
High-Frequency Sensorineural Hearing Loss The reported clinical endpoint includes this audiometric feature; this edge does not establish its genetic cause.
Bilateral Involvement The reported clinical endpoint includes this audiometric feature; this edge does not establish its genetic cause.
Show evidence (1 reference)
PMID:9843210 SUPPORT INDIRECT Human Clinical
"These findings suggest that mutations in GJB3 may be responsible for bilateral high-frequency hearing impairment."
Founding family association, explicitly tentative about causation.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Dominant Nonsyndromic Hearing Loss 2B Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

2
High-Frequency Sensorineural Hearing Loss Otologic HP:0005101 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is High-frequency hearing impairment (HP:0005101). HP:0005101 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:9843210 SUPPORT Human Clinical
"Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were associated with high-frequency hearing loss in two families."
The audiometric pattern in the two founding families.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1209/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Individuals from both families had bilateral sensorineural hearing loss (SNHL) characterized by a gently downsloping audiogram from normal hearing thresholds below 1,000 Hz to moderate hearing loss in the high frequencies."
The full DFNA2A chapter summarizes the founding GJB3 families. This is a phenotype description, not confirmation of the disputed genetic cause.
Bilateral Involvement Otologic HP:0008619 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bilateral sensorineural hearing impairment (HP:0008619). HP:0008619 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9843210 SUPPORT Human Clinical
"These findings suggest that mutations in GJB3 may be responsible for bilateral high-frequency hearing impairment."
States bilateral involvement, in the source's own hedged framing.
🧬

Genetic Associations

1
GJB3
Gene: GJB3 hgnc:4285 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GJB3 (hgnc:4285). hgnc:4285 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: DISPUTED
Show evidence (8 references)
CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z REFUTE Other
"In summary, there is convincing evidence disputing the association between GJB3 and autosomal dominant nonsyndromic hearing loss."
The classification this relationship_type encodes.
CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z SUPPORT Other
"Of note, this gene has also been implicated in Erythrokeratodermia variabilis."
The panel's own separation of the two GJB3 relationships, which is why the Disputed verdict is about this disease and not about the gene.
PMID:29926981 SUPPORT Human Clinical
"Putatively causative GJB3 variant underlied 1% (1/100) in this cohort."
One putative contribution in a selected cohort of 100 GJB2 heterozygotes, not an estimate of disease prevalence or evidence refuting rare causation.
+ 5 more references
🗃️

External Assertions

2
ClinGen GJB3-nonsyndromic hearing loss gene-disease validity assertion
ClinGen gene disease validity CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
The ClinGen Hearing Loss Gene Curation Expert Panel classifies the autosomal dominant GJB3-nonsyndromic hearing loss relationship as Disputed, approved 2018-02-27. Its evidence summary is unusually explicit about why: the association rested on case-level data only, many reported variants are present at high frequency in population databases or have no evidence for pathogenicity, and only three variants had enough evidence to score.
The same expert panel classifies GJB3-erythrokeratodermia variabilis as Definitive. One gene, two curations by the same group, opposite verdicts - which is the cleanest possible demonstration that a gene's disease relationships have to be assessed one at a time. The assertion's evidence summary cites PMID 12759707 among the publications in which the association was seen. Looked up at PubMed, that identifier is a 2003 Spanish-language editorial on smoking prevention in Anales del Sistema Sanitario de Navarra, so it is evidently a transcription error in the ClinGen record rather than a hearing-loss report. It is cited nowhere in this entry, and no attempt was made to guess which publication was intended.
Show evidence (6 references)
CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z REFUTE Other
"GJB3 | HGNC:4285 | nonsyndromic genetic hearing loss | MONDO:0019497 | AD | Disputed"
The expert-panel classification row, with the dominant mode of inheritance DFNA2B claims.
CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z REFUTE Other
"In summary, there is convincing evidence disputing the association between GJB3 and autosomal dominant nonsyndromic hearing loss."
The panel's conclusion sentence. Read together with the sentence that follows it and with the framework's published definition, quoted below: Disputed covers insufficient as well as contradictory evidence, and the panel explicitly declines to rule the reported evidence out.
CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z REFUTE Other
"Multiple missense and nonsense variants have been reported in humans, however many of these variants are present in high frequency in population databases and/or have no evidence for pathogenicity."
The specific reason the reported variant count overstates the evidence.
+ 3 more references
ClinGen GJB3-erythrokeratodermia variabilis gene-disease validity assertion
ClinGen gene disease validity CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
Recorded here for contrast, not because it is this disease. The same Hearing Loss Gene Curation Expert Panel rates GJB3's relationship with erythrokeratodermia variabilis Definitive, on a 2023 SOP v9 review - five years newer than the Disputed hearing-loss curation. dismech curates that disease separately as Erythrokeratodermia Variabilis.
Show evidence (1 reference)
CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z SUPPORT Other
"GJB3 | HGNC:4285 | erythrokeratodermia variabilis | MONDO:0017851 | AD | Definitive"
Establishes the established GJB3 disease, so a reader can see at a glance that the Disputed verdict above is specific to hearing loss and is not a judgement about the gene.
💊

Medical Actions

5
Hearing habilitation and communication support
Action: hearing aid fitting and auditory rehabilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hearing aid fitting and auditory rehabilitation, annotated with Rehabilitation (NCIT:C15315), qualified as Medical Device Hearing Aid. NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
Offer individualized hearing-aid fitting, communication and educational support for the observed hearing loss. These are general hearing-loss measures and do not establish GJB3 causality or a GJB3-specific treatment response.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"customized by an audiologist to the degree and frequency of hearing loss, can be used in individuals with mild-to-severe hearing loss."
This clause refers to hearing aids in the source. It is general rehabilitation guidance, not a DFNA2B efficacy study.
Cochlear implant assessment
Action: cochlear device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear device implantation, annotated with Surgical Procedure (NCIT:C15329), qualified as Medical Device Cochlear Implant. NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Assess implant candidacy according to age, hearing severity and communication needs. General guidance supports considering implantation in children with severe-to-profound hearing loss; no GJB3-specific benefit estimate is inferred.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Cochlear implantation can be considered in children with severe-to-profound hearing loss who are older than age nine months."
General pediatric candidacy statement; individual evaluation is required.
Audiologic follow-up
Follow hearing over time and adapt rehabilitation to documented stability or progression. A DFNA2B-specific surveillance interval cannot be assigned from the disputed association.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"Document the stability or progression of the hearing loss;"
Purpose of sequential audiologic examinations in the general overview.
Avoid repeated loud-noise overexposure
Counsel people with hearing loss to avoid repeated excessive noise exposure. This is a general precaution and does not establish a specific GJB3-environment interaction.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"persons with documented hearing loss should be counseled appropriately and repeated overexposure to loud noises should be avoided."
General hearing-loss precaution in the agents-to-avoid section.
Genetic counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Discuss uncertainty, family history, broader testing and reproductive questions. Allele transmission and disease recurrence are distinct when pathogenicity is unresolved; do not assign a 50% hearing-loss risk from a GJB3 variant alone.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical
"It is appropriate to offer genetic counseling (including discussion of the probability of hearing loss in offspring and reproductive options) to young adults who have hearing loss."
General counseling recommendation; a disputed GJB3 attribution cannot supply a validated disease recurrence risk.
🔬

Diagnosis

1
Interpretation of a GJB3 variant found on a deafness panel
Assess the hearing phenotype and pursue a multigene hearing-loss panel and/or genomic testing with variant interpretation appropriate to the family. KCNQ4, GJB2 and other established hearing-loss genes are alternatives; a particular audiogram does not establish the causal gene. A GJB3 variant, including an abnormal functional assay or a VUS, does not independently confirm DFNA2B. Additional GJB2 or SLC26A4 variants are not automatically alternative diagnoses without appropriate pathogenicity, genotype and phase. The former four-item checklist was not a validated diagnostic algorithm.
Show evidence (5 references)
PMID:29106878 SUPPORT Human Clinical
"Of the 5700 patients, 23 (0.40%) carried a GJB3 c.538C>T heterozygous variant; of these, 11 patients had other gene (GJB2/SLC26A4) mutations simultaneously."
Co-occurring variants motivate broader interpretation; their presence alone does not prove an alternative diagnosis.
PMID:29926981 SUPPORT Human Clinical
"GJB3/GJB6 variants account for a low proportion in autosomal recessive GJB2 mutation carriers in our cohort."
A study that asked directly whether GJB3 screening is worth doing and found the yield low.
PMID:20301388 SUPPORT Human Clinical
"The diagnosis of DFNA2 nonsyndromic hearing loss is established in an individual with a characteristic audioprofile, a family history consistent with autosomal dominant inheritance, and identification of a heterozygous pathogenic variant in KCNQ4."
KCNQ4 is an established differential; its diagnosis requires a pathogenic variant, not audiogram resemblance alone.
+ 2 more references
📊

Prevalence

1
Chinese hearing-loss cohorts
Carrier Frequency Unknown
Disease prevalence is unknown. In a Chinese series, p.Arg180* heterozygotes occurred in 23/5,700 hearing-loss cases (0.40%) and 11/4,600 normal-hearing controls (0.24%), without a significant difference. Eleven case carriers had additional GJB2 or SLC26A4 variants, which require their own genotype and pathogenicity assessment. No family history was reported, but this alone does not exclude dominant inheritance. A second study of 689 hearing-loss and 1,489 control subjects found p.Arg180* allele frequencies of 0.29% and 0.30%. Most participants were infants, limiting assessment of adult-onset effects. These are allele or carrier frequencies, not DFNA2B prevalence. A separate 284-patient survey sequenced GJB3 in 188 remaining patients and found V84I in two heterozygous cases and a homozygous normal-hearing control. A selected cohort of 100 GJB2 heterozygotes reported one putative GJB3 contribution; rarity alone neither confirms nor refutes causality.
Show evidence (5 references)
PMID:29106878 SUPPORT Human Clinical
"Of the 5700 patients, 23 (0.40%) carried a GJB3 c.538C>T heterozygous variant; of these, 11 patients had other gene (GJB2/SLC26A4) mutations simultaneously."
Observed carrier frequency and co-occurrence of other variants; the abstract does not establish that those variants explain each patient.
PMID:29106878 REFUTE Human Clinical
"There was no statistical difference in incidence between the two groups."
No significant case-control enrichment was detected for this allele; a nonsignificant result is not proof of no effect.
PMID:19744334 SUPPORT Human Clinical
"Mutations in GJB3, GJB6, and mtDNA tRNAser(UCN) were not common in this Chinese cohort."
Low variant frequency in this survey does not itself refute a rare disease. Full text distinguishes the 284-person cohort from the 188 sequenced for GJB3.
+ 2 more references
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Autosomal Dominant Nonsyndromic Hearing Loss 2B:

🔬

Clinical Trials

1
NCT06133946 NOT_APPLICABLE ACTIVE_NOT_RECRUITING
Prospective observational newborn screening cohort, not a therapeutic trial. The registry lists 35,920 enrolled infants and includes GJB3 c.538C>T among 15 screened variants. Its protocol labels this finding as a carrier result; it does not establish GJB3 causality or DFNA2B prevalence. Status checked 2026-09-23; registry last update 2023-11-18.
Show evidence (1 reference)
clinicaltrials:NCT06133946 SUPPORT Other
"This study was based on a concurrent newborn genetic and hearing screening program in Nantong city."
Registry study description establishes observational screening scope, not therapeutic efficacy.
🐁

Animal Models

1
Cx31-deficient (Gjb3 lacZ knock-in) mouse
Targeted Gjb3 replacement produced homozygous null mice. Many homozygous embryos were lost during placental development, but surviving adults had no reported morphological or functional defect of the inner ear or skin. Placental recovery coincided with increased Cx43 expression; compensation in adult tissues was the authors' interpretation. This null genotype does not test a heterozygous variant with toxic or dominant-interfering effects. Normal null skin is not a failed test of every dominant EKV mechanism.
Species
Mouse
Genotype
Gjb3(-/-), targeted replacement of Gjb3 by a lacZ reporter, homozygous
Publication
PMID:11237463
Pathograph links
Reported Sensorineural Hearing Loss fails to recapitulate fidelity: low Surviving adult null mice did not reproduce the auditory endpoint. The study did not directly measure the cell-culture coupling event represented elsewhere in this entry.
Limitations: Species differences, survivor selection, observation window and genotype limit extrapolation. Compensation is proposed, not a demonstrated cochlear mechanism. Human EKV variants have diverse effects, so the normal null skin result cannot calibrate all GJB3 disease models.
Readouts
Inner ear morphology and auditory function in adult Gjb3-null mice
Direction: UNCHANGED
Interpretation: Normal inner-ear morphology and function in surviving adult homozygous null mice; not a direct cochlear gap-junction assay.
Show evidence (1 reference)
PMID:11237463 REFUTE Model Organism
"No morphological or functional defects of skin or inner ear were observed in surviving adult Gjb3(-/-) mice."
Measured organismal negative result in surviving null animals.
Show evidence (1 reference)
PMID:11237463 REFUTE Model Organism
"No morphological or functional defects of skin or inner ear were observed in surviving adult Gjb3(-/-) mice."
Measured organismal negative result in surviving null animals.
{ }

Source YAML

click to show 
name: Autosomal Dominant Nonsyndromic Hearing Loss 2B
creation_date: "2026-08-28T22:00:00Z"
category: Mendelian
disease_term:
  preferred_term: autosomal dominant nonsyndromic hearing loss 2B
  term:
    id: MONDO:0012976
    label: autosomal dominant nonsyndromic hearing loss 2B
synonyms:
- DFNA2B
- deafness, autosomal dominant 2B
- GJB3-related autosomal dominant nonsyndromic hearing loss
- autosomal dominant nonsyndromic deafness 2B
description: >-
  DFNA2B denotes the proposed association between heterozygous GJB3 variants and autosomal dominant nonsyndromic
  hearing loss. The founding report described two families with bilateral high-frequency impairment. ClinGen
  classified the relationship Disputed in 2018; this classification remained listed when checked in September
  2026. It reflects insufficient or contradictory evidence, not proof that every GJB3 allele is harmless.
  Case-control studies did not find significant enrichment of the frequently screened p.Arg180* allele,
  but their variant selection and age distributions limit generalization. Selected connexin 31 variants
  show trafficking, cellular-stress or coupling abnormalities in expression systems, whereas surviving
  homozygous null mice have normal inner-ear morphology and function. These findings do not establish
  a human deafness mechanism. The separately curated GJB3-erythrokeratodermia variabilis relationship
  is Definitive. Hearing assessment, genetic evaluation and rehabilitation remain appropriate for the
  observed phenotype while its cause is unresolved.

parents:
- Autosomal Dominant Nonsyndromic Hearing Loss
- Hereditary Hearing Loss

external_assertions:
- name: ClinGen GJB3-nonsyndromic hearing loss gene-disease validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
  description: >-
    The ClinGen Hearing Loss Gene Curation Expert Panel classifies the autosomal dominant
    GJB3-nonsyndromic hearing loss relationship as Disputed, approved 2018-02-27. Its
    evidence summary is unusually explicit about why: the association rested on case-level
    data only, many reported variants are present at high frequency in population databases
    or have no evidence for pathogenicity, and only three variants had enough evidence to
    score.
  evidence:
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
    supports: REFUTE
    evidence_source: OTHER
    snippet: "GJB3 | HGNC:4285 | nonsyndromic genetic hearing loss | MONDO:0019497 | AD | Disputed"
    explanation: >-
      The expert-panel classification row, with the dominant mode of inheritance DFNA2B
      claims.
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      In summary, there is convincing evidence disputing the association between GJB3 and
      autosomal dominant nonsyndromic hearing loss.
    explanation: >-
      The panel's conclusion sentence. Read together with the sentence that follows it and
      with the framework's published definition, quoted below: Disputed covers insufficient
      as well as contradictory evidence, and the panel explicitly declines to rule the
      reported evidence out.
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      Multiple missense and nonsense variants have been reported in humans, however many of
      these variants are present in high frequency in population databases and/or have no
      evidence for pathogenicity.
    explanation: >-
      The specific reason the reported variant count overstates the evidence.
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      More evidence is needed to either support or refute the role GJB3 plays in this disease.
    explanation: >-
      The panel explicitly leaves the relationship unresolved; Disputed is not equivalent to Refuted.
  - reference: PMID:30894701
    reference_title: ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, the Disputed classification indicates that the expert panel reviewed the
      evidence and disputed the claim due to insufficient or contradictory evidence.
    explanation: >-
      The HL GCEP's own published definition of what Disputed means. It covers insufficient
      evidence as well as contradictory evidence, which is why this entry does not gloss the
      classification as a positive assertion that GJB3 is not a deafness gene.
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: "GJB3 / nonsyndromic genetic hearing loss (Disputed)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Association is seen in at least 5 probands in 3 publications
    explanation: >-
      A dated minimum in the 2018 assertion, not the exact worldwide total or evidence against the phenotype.
    directness: DIRECT
  notes: >-
    The same expert panel classifies GJB3-erythrokeratodermia variabilis as Definitive. One
    gene, two curations by the same group, opposite verdicts - which is the cleanest possible
    demonstration that a gene's disease relationships have to be assessed one at a time.

    The assertion's evidence summary cites PMID 12759707 among the publications in which the
    association was seen. Looked up at PubMed, that identifier is a 2003 Spanish-language
    editorial on smoking prevention in Anales del Sistema Sanitario de Navarra, so it is
    evidently a transcription error in the ClinGen record rather than a hearing-loss report.
    It is cited nowhere in this entry, and no attempt was made to guess which publication was
    intended.

- name: ClinGen GJB3-erythrokeratodermia variabilis gene-disease validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
  description: >-
    Recorded here for contrast, not because it is this disease. The same Hearing Loss Gene Curation Expert
    Panel rates GJB3's relationship with erythrokeratodermia variabilis Definitive, on a 2023 SOP v9 review
    - five years newer than the Disputed hearing-loss curation. dismech curates that disease separately
    as Erythrokeratodermia Variabilis.
  evidence:
  - reference: CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
    reference_title: GJB3 / erythrokeratodermia variabilis (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GJB3 | HGNC:4285 | erythrokeratodermia variabilis | MONDO:0017851 | AD | Definitive"
    explanation: >-
      Establishes the established GJB3 disease, so a reader can see at a glance that the
      Disputed verdict above is specific to hearing loss and is not a judgement about the
      gene.

prevalence:
- population: Chinese hearing-loss cohorts
  measure_type: CARRIER_FREQUENCY
  prevalence_class: UNKNOWN
  notes: >-
    Disease prevalence is unknown. In a Chinese series, p.Arg180* heterozygotes occurred in 23/5,700 hearing-loss
    cases (0.40%) and 11/4,600 normal-hearing controls (0.24%), without a significant difference. Eleven
    case carriers had additional GJB2 or SLC26A4 variants, which require their own genotype and pathogenicity
    assessment. No family history was reported, but this alone does not exclude dominant inheritance.
    A second study of 689 hearing-loss and 1,489 control subjects found p.Arg180* allele frequencies of
    0.29% and 0.30%. Most participants were infants, limiting assessment of adult-onset effects. These
    are allele or carrier frequencies, not DFNA2B prevalence. A separate 284-patient survey sequenced
    GJB3 in 188 remaining patients and found V84I in two heterozygous cases and a homozygous normal-hearing
    control. A selected cohort of 100 GJB2 heterozygotes reported one putative GJB3 contribution; rarity
    alone neither confirms nor refutes causality.
  evidence:
  - reference: PMID:29106878
    reference_title: The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of the 5700 patients, 23 (0.40%) carried a GJB3 c.538C>T heterozygous variant; of these,
      11 patients had other gene (GJB2/SLC26A4) mutations simultaneously.
    explanation: >-
      Observed carrier frequency and co-occurrence of other variants; the abstract does not establish
      that those variants explain each patient.
  - reference: PMID:29106878
    reference_title: The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no statistical difference in incidence between the two groups.
    explanation: >-
      No significant case-control enrichment was detected for this allele; a nonsignificant result is
      not proof of no effect.
  - reference: PMID:19744334
    reference_title: Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in GJB3, GJB6, and mtDNA tRNAser(UCN) were not common in this Chinese cohort.
    explanation: >-
      Low variant frequency in this survey does not itself refute a rare disease. Full text distinguishes
      the 284-person cohort from the 188 sequenced for GJB3.
  - reference: PMID:37964827
    reference_title: "Comparative analysis of allele frequencies of 15 deafness gene variants between hearing-loss and normal populations in Henan, China."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study showed that the allele frequency of GJB3 c.538C > T variant was 0.29 % in the HL group
      and 0.30 % in the NC group (Table .3), and the difference in allele frequency between these two
      groups was not statistically significant.
    explanation: >-
      Within-study comparison, rather than the gnomAD comparison. The 15-variant panel and predominantly
      infant population limit inference about other alleles and later-onset hearing loss.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:19744334
    reference_title: Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GJB3 was sequenced in the remaining 188 patients.
    explanation: >-
      Full-text methods denominator: the study enrolled 284 patients overall but sequenced GJB3 in the
      remaining 188 after earlier testing.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
mechanistic_hypotheses:
- hypothesis_group_id: cx31_gap_junction_deafness
  hypothesis_label: >-
    Trafficking-defective connexin 31 disrupts cochlear gap-junction coupling and causes
    dominant high-frequency hearing loss
  status: ALTERNATIVE
  description: >-
    Selected GJB3 variants alter connexin 31 localization, induce cellular stress or reduce coupling in
    transfected cells. These effects provide a candidate molecular basis for the disputed auditory association,
    but neither expression in auditory tissue nor abnormal heterozygous coexpression proves clinical pathogenicity
    or a dominant-negative mechanism. Dominant disease could involve dosage reduction, dominant interference
    or toxic gain of function. The normal hearing of surviving Gjb3-null mice challenges a simple loss-of-function
    model but does not test a heterozygous toxic missense allele. The cited evidence does not establish
    the proposed cellular-to-human auditory chain.
  evidence:
  - reference: PMID:21204020
    reference_title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Together, the HI-associated C×31 mutants are impaired in trafficking, promote ER
      stress, and hence lose the ability to assemble functional gap junctions.
    explanation: >-
      The molecular half of the hypothesis, measured in transfected cells.
  - reference: PMID:11237463
    reference_title: Connexin31-deficiency in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      No morphological or functional defects of skin or inner ear were observed in surviving
      adult Gjb3(-/-) mice.
    explanation: >-
      Normal inner-ear function in surviving null mice challenges simple loss of function. Species, genotype
      and survivor selection limit extrapolation to heterozygous human alleles. Normal null skin does
      not test the diverse dominant mechanisms reported for EKV.

    directness: INDIRECT
pathophysiology:
- name: Heterozygous GJB3 Variant
  role: trigger
  biological_scale: MOLECULAR
  description: >-
    The founding report associated heterozygous missense and nonsense GJB3 variants with hearing loss
    in two families. GJB3 encodes connexin 31. Selected variants have measurable effects in expression
    systems, but clinical pathogenicity and penetrance remain disputed; heterozygosity alone does not
    establish causation or select among dosage, dominant-negative and toxic gain-of-function mechanisms.
    The frequently screened c.538C>T (p.Arg180*) allele lacked significant enrichment in subsequent case-control
    studies.
  genetic_context:
    gene:
      preferred_term: GJB3
      term:
        id: hgnc:4285
        label: GJB3
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    description: >-
      Heterozygous in the reported families. functional_impact_category is omitted
      deliberately: the trafficking data show the mutant protein is made and mislocalised
      rather than absent, and whether that constitutes loss of function or a dominant
      negative is the open question rather than something the entry can assert.
  downstream:
  - target: Connexin 31 Intracellular Trafficking Abnormality
    causal_link_type: DIRECT
    hypothesis_groups:
    - cx31_gap_junction_deafness
    description: >-
      Two hearing-loss-associated variants have been shown to do this directly in transfected
      cells.
  - target: Connexin 31-Associated Endoplasmic Reticulum Stress
    causal_link_type: DIRECT
    hypothesis_groups:
    - cx31_gap_junction_deafness
    description: >-
      Selected mutant constructs induced BiP responses in transfected cells.
    evidence:
    - reference: PMID:21204020
      reference_title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Expression of C×31 mutants but not C×31wt leads to upregulation of and increased association with
        the ER chaperone BiP indicating ER stress induction.
      explanation: >-
        BiP response and association support ER stress in the expression system.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: V174M-Associated Interference with Connexin 26 Trafficking
    causal_link_type: DIRECT
    hypothesis_groups:
    - cx31_gap_junction_deafness
    description: >-
      V174M-specific coexpression result; not a property assigned to all GJB3 alleles.
    evidence:
    - reference: PMID:24913888
      reference_title: "Mechanism of a novel missense mutation, p.V174M, of the human connexin31 (GJB3) in causing nonsyndromic hearing loss."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        CX31V174M co-expressed with either CX31WT or CX26WT studies, suggested the impairment of the ability
        of CX26WT proteins to intracellular trafficking and targeting to the plasma membrane, but did
        not influence the trafficking of CX31WT.
      explanation: >-
        Differential effect on two wild-type connexins in the coexpression system.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  evidence:
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were
      associated with high-frequency hearing loss in two families.
    explanation: >-
      The founding association, on two families.
  - reference: PMID:29106878
    reference_title: The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results showed that the GJB3 c.538C>T variant has a very low incidence in the
      Chinese population, and there was no clear evidence to support a role of the GJB3
      c.538C>T variant in the autosomal dominant form of non-syndromic deafness.
    explanation: >-
      The authors found no clear support for this particular allele as a dominant cause; this does not
      establish a result for every GJB3 variant.
- name: Connexin 31 Intracellular Trafficking Abnormality
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    R180X accumulated primarily in the endoplasmic reticulum and E183K in Golgi-like punctate structures
    in transfected cells. V174M accumulated in lysosomes in HeLa cells. Intracellular localization therefore
    differs by variant and is not uniformly ER retention. These findings concern selected expression constructs,
    not demonstrated human cochlear lesions. EKV-associated variants have diverse cellular effects and
    should not all be assigned this same mechanism.
  downstream:
  - target: Reduced Connexin 31-Mediated Coupling in Expression Systems
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - cx31_gap_junction_deafness
    description: >-
      Trafficking abnormalities and deficient coupling co-occur in mutant expression systems. The cited
      experiments do not isolate localization from every other effect of the variants.
  evidence:
  - reference: PMID:21204020
    reference_title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast, two HI-associated C×31 mutants, C×31R180X and C×31E183K resided primarily
      in the ER and Golgi-like intracellular punctate structures, respectively, and failed to
      mediate lucifer yellow transfer.
    explanation: >-
      The retention and dye-transfer failure, in transfected cells.
  - reference: PMID:21204020
    reference_title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In transfected cells, wild type C×31 protein (C×31wt) forms functional gap junction at
      cell-cell-contacts.
    explanation: >-
      The wild-type control that makes the mutant result interpretable.

  - reference: PMID:24913888
    reference_title: "Mechanism of a novel missense mutation, p.V174M, of the human connexin31 (GJB3) in causing nonsyndromic hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Conversely, the p.V174M missense mutation resulted in the accumulation of the mutant protein in
      the lysosomes rather than in the cytoplasmic membrane.
    explanation: >-
      Variant-specific lysosomal accumulation in HeLa cells; the clinical gene-disease relationship remains
      disputed.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Connexin 31-Associated Endoplasmic Reticulum Stress
  biological_scale: CELLULAR
  description: >-
    Expression of R180X and E183K increased the ER chaperone BiP and its association with connexin 31.
    This is a cellular stress response in transfected cells; its contribution to human hearing loss has
    not been established.
  evidence:
  - reference: PMID:21204020
    reference_title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Expression of C×31 mutants but not C×31wt leads to upregulation of and increased association with
      the ER chaperone BiP indicating ER stress induction.
    explanation: >-
      BiP response and association support ER stress in the expression system.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: V174M-Associated Interference with Connexin 26 Trafficking
  biological_scale: CELLULAR
  description: >-
    In HeLa coexpression experiments, V174M interfered with wild-type Cx26 trafficking and membrane targeting
    but did not alter wild-type Cx31 trafficking. The authors proposed trans-dominant-negative interference;
    this is not equivalent to demonstrated dominant-negative inhibition of Cx31 or proof of deafness in
    carriers.
  evidence:
  - reference: PMID:24913888
    reference_title: "Mechanism of a novel missense mutation, p.V174M, of the human connexin31 (GJB3) in causing nonsyndromic hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      CX31V174M co-expressed with either CX31WT or CX26WT studies, suggested the impairment of the ability
      of CX26WT proteins to intracellular trafficking and targeting to the plasma membrane, but did not
      influence the trafficking of CX31WT.
    explanation: >-
      Differential effect on two wild-type connexins in the coexpression system.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Reduced Connexin 31-Mediated Coupling in Expression Systems
  role: central_effector
  biological_scale: CELLULAR
  description: >-
    Selected mutants reduce intercellular dye transfer or ionic coupling in heterologous expression systems.
    V27M and V84I did not function normally when coexpressed with wild-type Cx31; this does not independently
    establish dominant-negative action or clinical pathogenicity. V174M did not form functional dye-transferring
    channels and interfered with Cx26 trafficking while sparing Cx31 wild-type trafficking. Mouse localization
    and rat transcript data support auditory expression, not direct demonstration of gap-junction coupling
    between inner hair cells or spiral ganglion neurons.
  molecular_functions:
  - preferred_term: connexin 31 gap junction channel activity
    term:
      id: GO:0005243
      label: gap junction channel activity
    modifier: DECREASED
  downstream:
  - target: Reported Sensorineural Hearing Loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - cx31_gap_junction_deafness
    description: >-
      This proposed bridge from cell-culture coupling defects to human hearing loss remains unestablished.
      Normal hearing in null mice limits a simple loss-of-function explanation.
  evidence:
  - reference: PMID:21204020
    reference_title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we show that expression of C×31 in the mouse inner ear is developmentally regulated
      with a high level in adult inner hair cells and spiral ganglion neurons that are
      critical for the hearing process.
    explanation: >-
      Auditory expression in mouse tissue provides context; it does not demonstrate functional coupling
      between these cell types.
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
  - reference: PMID:22617145
    reference_title: Evaluation of the pathogenicity of GJB3 and GJB6 variants associated with nonsyndromic hearing loss.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The results of biochemical and ionic coupling tests showed that both the Cx31-p.V27M and
      Cx31-p.V84I variants did not function normally when each was expressed as a heterozygote
      with the wild-type Cx31.
    explanation: >-
      Abnormal biochemical and ionic coupling under coexpression; not a sufficient demonstration of dominant-negative
      interference or human causality.
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Moreover, expression of Gjb3 was identified in rat inner ear tissue by RT-PCR.
    explanation: >-
      Expression in the inner ear, graded INDIRECT because presence of a transcript is
      consistent with a role and does not establish one.
  - reference: PMID:24913888
    reference_title: "Mechanism of a novel missense mutation, p.V174M, of the human connexin31 (GJB3) in causing nonsyndromic hearing loss."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Moreover, dye transfer experiments have also demonstrated that the CX31V174M mutant did not form
      functional gap junction channels, probably due to the incorrect assembly or the altered properties
      of the CX31 channels.
    explanation: >-
      Dye-transfer deficiency is measured; the assembly explanation is proposed.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Reported Sensorineural Hearing Loss
  role: consequence
  biological_scale: ORGANISM
  description: >-
    Bilateral high-frequency hearing loss was reported in the two founding families. Progressive or later-onset
    descriptions in reviews are not a validated natural-history series for a molecularly confirmed DFNA2B
    cohort. The clinical observations can be recorded without accepting the disputed attribution to GJB3.
  evidence:
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings suggest that mutations in GJB3 may be responsible for bilateral
      high-frequency hearing impairment.
    explanation: >-
      Founding family association, explicitly tentative about causation.
    directness: INDIRECT
  downstream:
  - target: High-Frequency Sensorineural Hearing Loss
    causal_link_type: DIRECT
    description: >-
      The reported clinical endpoint includes this audiometric feature; this edge does not establish its
      genetic cause.
  - target: Bilateral Involvement
    causal_link_type: DIRECT
    description: >-
      The reported clinical endpoint includes this audiometric feature; this edge does not establish its
      genetic cause.
phenotypes:
- category: Otologic
  name: High-Frequency Sensorineural Hearing Loss
  description: >-
    High-frequency bilateral hearing loss was reported in the founding families. A reliable frequency
    among pathogenic-variant carriers cannot be assigned while causality and penetrance are unresolved.
    Hearing-loss severity and audiogram frequency configuration are distinct measurements.
  phenotype_term:
    preferred_term: High-frequency hearing impairment
    term:
      id: HP:0005101
      label: High-frequency hearing impairment
  evidence:
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were
      associated with high-frequency hearing loss in two families.
    explanation: >-
      The audiometric pattern in the two founding families.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1209/?report=reader
    reference_title: DFNA2 Nonsyndromic Hearing Loss - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals from both families had bilateral sensorineural hearing loss (SNHL) characterized by
      a gently downsloping audiogram from normal hearing thresholds below 1,000 Hz to moderate hearing
      loss in the high frequencies.
    explanation: >-
      The full DFNA2A chapter summarizes the founding GJB3 families. This is a phenotype description,
      not confirmation of the disputed genetic cause.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- category: Otologic
  name: Bilateral Involvement
  phenotype_term:
    preferred_term: Bilateral sensorineural hearing impairment
    term:
      id: HP:0008619
      label: Bilateral sensorineural hearing impairment
  description: >-
    Both ears, in the reported families.
  evidence:
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings suggest that mutations in GJB3 may be responsible for bilateral
      high-frequency hearing impairment.
    explanation: >-
      States bilateral involvement, in the source's own hedged framing.

genetic:
- name: GJB3
  gene_term:
    preferred_term: GJB3
    term:
      id: hgnc:4285
      label: GJB3
  relationship_type: DISPUTED
  notes: >-
    ClinGen classifies the dominant nonsyndromic hearing-loss relationship as DISPUTED, distinct from
    the definitive EKV relationship. A GJB3 variant alone is not a confirmed molecular diagnosis of hearing
    loss. Missense and truncating alleles have been reported, but variant-specific functional effects
    do not resolve the gene-disease dispute. The common screening allele p.Arg180* was classified VUS
    in the 2023 case-control paper. GJB2/SLC26A4 co-occurrence requires independent assessment of pathogenicity,
    zygosity and phase. A 2018 family report proposed digenic GJB2/GJB3 inheritance after testing 127
    hearing-loss genes; this is a proposed multigenic explanation, not confirmation of monogenic DFNA2B.
    A 2022 R98H family had diverse skin and auditory phenotypes; the son with hearing loss received limited
    hotspot testing, whereas exome sequencing was performed only in the mother and daughter. Alternative
    causes in the son were not comprehensively excluded.
  evidence:
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      In summary, there is convincing evidence disputing the association between GJB3 and
      autosomal dominant nonsyndromic hearing loss.
    explanation: >-
      The classification this relationship_type encodes.
  - reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
    reference_title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Of note, this gene has also been implicated in Erythrokeratodermia variabilis.
    explanation: >-
      The panel's own separation of the two GJB3 relationships, which is why the Disputed
      verdict is about this disease and not about the gene.
  - reference: PMID:29926981
    reference_title: "GJB3/GJB6 screening in GJB2 carriers with idiopathic hearing loss: Is it necessary?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Putatively causative GJB3 variant underlied 1% (1/100) in this cohort.
    explanation: >-
      One putative contribution in a selected cohort of 100 GJB2 heterozygotes, not an estimate of disease
      prevalence or evidence refuting rare causation.
  - reference: PMID:37964827
    reference_title: "Comparative analysis of allele frequencies of 15 deafness gene variants between hearing-loss and normal populations in Henan, China."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "our study confirmed that GJB3 c.538C > T variant may not be the disease-causing variant of hearing loss."
    explanation: >-
      This independent Chinese case-control study found no significant enrichment of p.Arg180*,
      one of the two founding alleles. The 15-variant panel and predominantly infant cohort limit
      inference about other alleles and later-onset loss; non-significance does not establish absence
      of an effect.
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GJB3 was mapped to human chromosome 1p33-p35.
    explanation: >-
      The gene's map position, established in the founding study.

  - reference: PMID:29926981
    reference_title: "GJB3/GJB6 screening in GJB2 carriers with idiopathic hearing loss: Is it necessary?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In family GDHY, we identified a rare GJB3 c.250G>A mutation, as double heterozygotes with GJB2 c.109G>A
      and/or a novel GJB2 mutation c.638T>C predicted to be damaging in a digenic inheritance after precluding
      other attributable mutations from 127 deafness genes.
    explanation: >-
      The authors proposed digenic inheritance. Their association and predictions do not establish monogenic
      GJB3 disease.
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
  - reference: PMID:19744334
    reference_title: Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: One control subject was homozygous for 250A>G (V84I).
    explanation: >-
      A normal-hearing homozygous V84I control limits attribution of this variant. The nucleotide notation
      is reproduced exactly from this source, which differs from the later report; this entry uses the
      protein name in its synthesis.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
  - reference: PMID:35677558
    reference_title: "A Connexin Gene (GJB3) Mutation in a Chinese Family With Erythrokeratodermia Variabilis, Ichthyosis and Nonsyndromic Hearing Loss: Case Report and Mutations Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sanger sequencing was performed in the proband’s brother for hot spot variants in NSHL-related genes
      (GJB2, GJB3, SLC26A4, and MT-RNR1).
    explanation: >-
      Full methods identify the limited testing of the son with hearing loss. The mother and daughter
      underwent exome sequencing, so alternative causes in the son were not comparably excluded.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Autosomal dominant inheritance is the proposed historical model, not a confirmed recurrence-risk model
    for a GJB3 finding. Absence of reported family history in all 23 p.Arg180* carriers in one cohort
    supplies no segregation support, but does not logically exclude dominant inheritance: family ascertainment,
    age-dependent penetrance or de novo occurrence can affect pedigrees. A 50% chance of transmitting
    a heterozygous allele must not be presented as a 50% chance of GJB3-related hearing loss while pathogenicity
    is unresolved.
  evidence:
  - reference: PMID:9843210
    reference_title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutation analysis revealed that a missense mutation and a nonsense mutation of GJB3 were
      associated with high-frequency hearing loss in two families.
    explanation: >-
      The family-based observation underlying the dominant claim.
  - reference: PMID:29106878
    reference_title: The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 23 patients were sporadic cases and had no family history of deafness.
    explanation: >-
      Documents absence of reported family history; it is not direct refutation of dominant inheritance.

    quote_role: PRIMARY_RESULT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is appropriate to offer genetic counseling (including discussion of the probability of hearing
      loss in offspring and reproductive options) to young adults who have hearing loss.
    explanation: >-
      General counseling recommendation; a disputed GJB3 attribution cannot supply a validated disease
      recurrence risk.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
animal_models:
- name: Cx31-deficient (Gjb3 lacZ knock-in) mouse
  species: Mouse
  genotype: Gjb3(-/-), targeted replacement of Gjb3 by a lacZ reporter, homozygous
  publication: PMID:11237463
  description: >-
    Targeted Gjb3 replacement produced homozygous null mice. Many homozygous embryos were lost during
    placental development, but surviving adults had no reported morphological or functional defect of
    the inner ear or skin. Placental recovery coincided with increased Cx43 expression; compensation in
    adult tissues was the authors' interpretation. This null genotype does not test a heterozygous variant
    with toxic or dominant-interfering effects. Normal null skin is not a failed test of every dominant
    EKV mechanism.
  modeled_mechanisms:
  - target: Reported Sensorineural Hearing Loss
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      Surviving adult null mice did not reproduce the auditory endpoint. The study did not directly measure
      the cell-culture coupling event represented elsewhere in this entry.
    limitations: >-
      Species differences, survivor selection, observation window and genotype limit extrapolation. Compensation
      is proposed, not a demonstrated cochlear mechanism. Human EKV variants have diverse effects, so
      the normal null skin result cannot calibrate all GJB3 disease models.
    readouts:
    - name: Inner ear morphology and auditory function in adult Gjb3-null mice
      target: Reported Sensorineural Hearing Loss
      direction: UNCHANGED
      interpretation: >-
        Normal inner-ear morphology and function in surviving adult homozygous null mice; not a direct
        cochlear gap-junction assay.
      evidence:
      - reference: PMID:11237463
        reference_title: Connexin31-deficiency in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation.
        supports: REFUTE
        evidence_source: MODEL_ORGANISM
        snippet: >-
          No morphological or functional defects of skin or inner ear were observed in
          surviving adult Gjb3(-/-) mice.
        explanation: >-
          Measured organismal negative result in surviving null animals.
    evidence:
    - reference: PMID:11237463
      reference_title: Connexin31-deficiency in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation.
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: >-
        No morphological or functional defects of skin or inner ear were observed in
        surviving adult Gjb3(-/-) mice.
      explanation: >-
        Measured organismal negative result in surviving null animals.
diagnosis:
- name: Interpretation of a GJB3 variant found on a deafness panel
  description: >-
    Assess the hearing phenotype and pursue a multigene hearing-loss panel and/or genomic testing with
    variant interpretation appropriate to the family. KCNQ4, GJB2 and other established hearing-loss genes
    are alternatives; a particular audiogram does not establish the causal gene. A GJB3 variant, including
    an abnormal functional assay or a VUS, does not independently confirm DFNA2B. Additional GJB2 or SLC26A4
    variants are not automatically alternative diagnoses without appropriate pathogenicity, genotype and
    phase. The former four-item checklist was not a validated diagnostic algorithm.
  evidence:
  - reference: PMID:29106878
    reference_title: The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of the 5700 patients, 23 (0.40%) carried a GJB3 c.538C>T heterozygous variant; of these,
      11 patients had other gene (GJB2/SLC26A4) mutations simultaneously.
    explanation: >-
      Co-occurring variants motivate broader interpretation; their presence alone does not prove an alternative
      diagnosis.
  - reference: PMID:29926981
    reference_title: "GJB3/GJB6 screening in GJB2 carriers with idiopathic hearing loss: Is it necessary?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GJB3/GJB6 variants account for a low proportion in autosomal recessive GJB2 mutation
      carriers in our cohort.
    explanation: >-
      A study that asked directly whether GJB3 screening is worth doing and found the yield
      low.
  - reference: PMID:20301388
    reference_title: DFNA2 Nonsyndromic Hearing Loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of DFNA2 nonsyndromic hearing loss is established in an individual with a
      characteristic audioprofile, a family history consistent with autosomal dominant
      inheritance, and identification of a heterozygous pathogenic variant in KCNQ4.
    explanation: >-
      KCNQ4 is an established differential; its diagnosis requires a pathogenic variant, not audiogram
      resemblance alone.

  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The identification of variant(s) of uncertain significance cannot be used to confirm or rule out
      the diagnosis.
    explanation: >-
      General genetic hearing-loss interpretation guidance; directly relevant to unresolved GJB3 findings.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      does not require the clinician to determine which gene is likely involved.
    explanation: >-
      This clause is explicitly about genomic testing in the source; inline HTML separates its heading.
      It supports broader testing rather than presuming a GJB3 cause.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
differential_diagnoses:
- name: DFNA2A - KCNQ4-related autosomal dominant nonsyndromic hearing loss
  description: >-
    KCNQ4-related DFNA2A is an established cause of progressive, predominantly high-frequency hearing
    loss in the original DFNA2 region. It belongs in broader genetic evaluation. Audiogram-based prediction
    can prioritize testing but is not specific enough to assign causation: the AudioGene validation identified
    KCNQ4 variants in only three of 48 predicted DFNA2 families (positive predictive value 6.3%). The
    GJB3 founding families had not excluded KCNQ4 when first reported.
  evidence:
  - reference: PMID:20301388
    reference_title: DFNA2 Nonsyndromic Hearing Loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DFNA2 nonsyndromic hearing loss is characterized by symmetric, predominantly
      high-frequency sensorineural hearing loss (SNHL) that is progressive across all
      frequencies.
    explanation: >-
      The DFNA2A phenotype, which is the phenotype DFNA2B is described as having. That two
      loci in one mapped interval carry the same audiogram is why the differential matters.
  - reference: PMID:20301388
    reference_title: DFNA2 Nonsyndromic Hearing Loss.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of DFNA2 nonsyndromic hearing loss is established in an individual with a
      characteristic audioprofile, a family history consistent with autosomal dominant
      inheritance, and identification of a heterozygous pathogenic variant in KCNQ4.
    explanation: >-
      The established diagnostic criteria for the alternative, against which the DFNA2B claim
      has none.
  - reference: PMID:18941426
    reference_title: Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Those families predicted to have a DFNA2 audioprofile by AudioGene v2.0 were screened
      for mutations in the KCNQ4 gene.
    explanation: >-
      The audioprofile was used to prioritize KCNQ4 screening. The low positive predictive value
      reported in the same study limits discrimination and requires molecular confirmation.

  - reference: PMID:18941426
    reference_title: Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two novel missense mutations and a stop mutation were detected in three American families predicted
      to have DFNA2-related deafness for a positive predictive value of 6.3%.
    explanation: >-
      The predictive value limits audiogram-based inference; molecular confirmation is required.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Erythrokeratodermia variabilis (GJB3-related)
  description: >-
    GJB3-related erythrokeratodermia variabilis is a separately curated skin disease with Definitive ClinGen
    validity. Its variant mechanisms are diverse and cannot all be equated with the auditory trafficking
    hypothesis. In the R98H family report, the mother had ichthyosis, the daughter EKV and the son hearing
    loss. This co-occurrence is hypothesis-generating; limited testing of the son and absence of variant-specific
    functional validation prevent a secure auditory attribution.
  evidence:
  - reference: CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
    reference_title: GJB3 / erythrokeratodermia variabilis (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      GJB3 | HGNC:4285 | erythrokeratodermia variabilis | MONDO:0017851 | AD | Definitive
    explanation: >-
      The expert-panel verdict on the differential entity, five years newer than the Disputed
      hearing-loss curation.
  - reference: PMID:35677558
    reference_title: "A Connexin Gene (GJB3) Mutation in a Chinese Family With Erythrokeratodermia Variabilis, Ichthyosis and Nonsyndromic Hearing Loss: Case Report and Mutations Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutation analysis revealed all of them carried a heterozygous missense mutation c.293G>A
      of GJB3.
    explanation: >-
      A shared allele and differing phenotypes in one family; causation of the son's hearing loss remains
      unresolved.
    directness: INDIRECT
  - reference: PMID:35677558
    reference_title: "A Connexin Gene (GJB3) Mutation in a Chinese Family With Erythrokeratodermia Variabilis, Ichthyosis and Nonsyndromic Hearing Loss: Case Report and Mutations Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The variation of clinical features may involve with genetic, epigenetic and environmental
      factors.
    explanation: >-
      The authors' own account of why one allele gave three phenotypes, which is a statement of
      not knowing.

- name: GJB2-related nonsyndromic hearing loss (DFNB1)
  description: >-
    GJB2-related hearing loss is an established alternative. In one GJB3 p.Arg180* series, 11 of 23 carriers
    also had GJB2 or SLC26A4 variants, but the abstract does not establish a complete alternative molecular
    diagnosis in each patient. Connexin-family membership or variant co-occurrence alone does not demonstrate
    digenic inheritance.
  evidence:
  - reference: PMID:22617145
    reference_title: Evaluation of the pathogenicity of GJB3 and GJB6 variants associated with nonsyndromic hearing loss.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Connexins (Cx26 encoded by GJB2, Cx31 encoded by GJB3 and Cx30 encoded by GJB6) are core
      components of gap junctions in the inner ear.
    explanation: >-
      Names the three connexins that are screened and interpreted together, which is where the
      confusion arises. Graded OTHER because this sentence is background from the paper's
      introduction and reports no study of its own; the same paper's coupling result is graded
      IN_VITRO elsewhere in this entry.

    quote_role: BACKGROUND
discussions:
- discussion_id: gap_gjb3_dominant_negative_untested_in_vivo
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#GJB3
  - mechanistic_hypotheses#cx31_gap_junction_deafness
  prompt: >-
    Does a heterozygous trafficking-defective GJB3 allele cause hearing loss in any organism?
  rationale: >-
    The cited cell studies measure selected variant effects, while the cited in-vivo study tests a homozygous
    null. Heterozygous knock-in studies with age-appropriate auditory measurements could test variant-specific
    effects, but positive hearing loss alone would not distinguish dominant interference from toxic gain
    of function. Negative results for one allele or model would not resolve every human GJB3 association.
  proposed_experiments:
  - experiment_id: gjb3_knockin_heterozygote_auditory_phenotype
    name: Auditory phenotyping of mice heterozygous for a human DFNA2B GJB3 allele
    description: >-
      Compare heterozygous R180X or E183K knock-in mice with wild-type, heterozygous-null and homozygous-null
      controls across age and frequency. Measure auditory function and variant expression, connexin localization
      and coupling. Use coexpression and rescue experiments to distinguish interference with wild-type
      protein from other toxic effects.
    would_support:
    - mechanistic_hypotheses#cx31_gap_junction_deafness
    supporting_outcome:
    - >-
      A reproducible auditory phenotype linked to a specific knock-in would support that allele's in-vivo
      effect. Dominant-negative attribution would additionally require evidence of interference with wild-type
      function.
    refuting_outcome:
    - >-
      Normal hearing with verified expression and adequate observation would weaken that allele-specific
      mouse mechanism, without proving absence of human disease or justifying retirement of all DFNA2B
      associations.
- discussion_id: mismatch_gjb3_null_mouse_normal_in_skin_too
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - animal_models#Cx31-deficient (Gjb3 lacZ knock-in) mouse
  prompt: >-
    How do genotype, species and compensation limit interpretation of normal hearing in the Gjb3-null
    mouse?
  rationale: >-
    The null study reports normal adult skin and inner ear, but dominant EKV variants have diverse cellular
    effects. A null does not test every dominant variant mechanism in either organ. Proposed compensation
    and species differences require direct study; neither normal skin nor an EKV knock-in result automatically
    validates or invalidates an auditory model.
  proposed_experiments:
  - experiment_id: gjb3_null_mouse_skin_and_ear_reassessment
    name: Reassessment of the Gjb3-null mouse against the established skin phenotype
    description: >-
      Compare null and selected disease-variant genotypes with matched controls using skin and auditory
      assays, expression measurements and connexin localization. Test candidate compensation directly
      instead of assuming that a shared lack of phenotype establishes it.
    would_support:
    - animal_models#Cx31-deficient (Gjb3 lacZ knock-in) mouse
    supporting_outcome:
    - >-
      Reproducible genotype-specific differences would define which mechanisms and tissues the models
      capture; a skin phenotype would not independently establish auditory-model sensitivity.
    refuting_outcome:
    - >-
      Failure to reproduce a selected phenotype would identify a limitation of that genotype and assay,
      not prove that all mouse Gjb3 models are uninformative.
notes: >-
  DFNA2B remains a disputed auditory gene-disease relationship. The clinically established GJB3 skin disease
  is represented only as a differential and external assertion, not as a DFNA2B phenotype. Molecular effects
  in transfected cells, mouse auditory expression, human family associations and null-mouse outcomes are
  graded separately. Functional abnormalities do not override population, segregation or clinical-validity
  uncertainty. No robust disease prevalence, penetrance estimate or variant-confirmed natural-history
  series is inferred.

  The full Genetic Hearing Loss Overview is used for phenotype-directed diagnosis, rehabilitation, surveillance,
  counseling and noise precautions. The full DFNA2A GeneReviews chapter discusses the weak GJB3 evidence
  and the founding-family phenotype; it is not a GJB3-specific chapter. Neither source establishes GJB3-specific
  treatment efficacy. The observational newborn registry is included for its screening relevance, not
  as an intervention study.

  The ClinGen hearing-loss assertion cites PMID 12759707, independently checked at PubMed as a smoking-prevention
  editorial rather than a hearing-loss paper. It is not used as evidence, and the intended identifier
  is not guessed. Selected functional sources remained abstract-only after refetching; relevant full texts
  were used for case-control results, family testing limits, predictive performance and clinical baseline
  care.

references:
- reference: PMID:9843210
  title: Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
- reference: PMID:11237463
  title: Connexin31-deficiency in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation.
- reference: PMID:21204020
  title: Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
- reference: PMID:22617145
  title: Evaluation of the pathogenicity of GJB3 and GJB6 variants associated with nonsyndromic hearing loss.
- reference: PMID:29106878
  title: The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
- reference: PMID:29926981
  title: "GJB3/GJB6 screening in GJB2 carriers with idiopathic hearing loss: Is it necessary?"
- reference: PMID:37964827
  title: "Comparative analysis of allele frequencies of 15 deafness gene variants between hearing-loss and normal populations in Henan, China."
- reference: PMID:19744334
  title: Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China.
- reference: PMID:35677558
  title: "A Connexin Gene (GJB3) Mutation in a Chinese Family With Erythrokeratodermia Variabilis, Ichthyosis and Nonsyndromic Hearing Loss: Case Report and Mutations Update."
- reference: PMID:30894701
  title: ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs.
- reference: PMID:20301388
  title: DFNA2 Nonsyndromic Hearing Loss.
  tags:
  - GeneReviews
- reference: PMID:18941426
  title: Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus.
- reference: CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
  title: GJB3 / nonsyndromic genetic hearing loss (Disputed)
- reference: CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
  title: GJB3 / erythrokeratodermia variabilis (Definitive)
- reference: PMID:24913888
  title: "Mechanism of a novel missense mutation, p.V174M, of the human connexin31 (GJB3) in causing nonsyndromic hearing loss."
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
  title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1209/?report=reader
  title: DFNA2 Nonsyndromic Hearing Loss - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
- reference: clinicaltrials:NCT06133946
  title: "Cohort of Universal Newborn Deafness-gene Screening in Nantong City, China"
treatments:
- name: Hearing habilitation and communication support
  description: >-
    Offer individualized hearing-aid fitting, communication and educational support for the observed hearing
    loss. These are general hearing-loss measures and do not establish GJB3 causality or a GJB3-specific
    treatment response.
  treatment_term:
    preferred_term: hearing aid fitting and auditory rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
    qualifiers:
    - predicate:
        preferred_term: Medical Device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: Hearing Aid
        term:
          id: NCIT:C183182
          label: Hearing Aid
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      customized by an audiologist to the degree and frequency of hearing loss, can be used in individuals
      with mild-to-severe hearing loss.
    explanation: >-
      This clause refers to hearing aids in the source. It is general rehabilitation guidance, not a DFNA2B
      efficacy study.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Cochlear implant assessment
  description: >-
    Assess implant candidacy according to age, hearing severity and communication needs. General guidance
    supports considering implantation in children with severe-to-profound hearing loss; no GJB3-specific
    benefit estimate is inferred.
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
    qualifiers:
    - predicate:
        preferred_term: Medical Device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: Cochlear Implant
        term:
          id: NCIT:C157820
          label: Cochlear Implant
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cochlear implantation can be considered in children with severe-to-profound hearing loss who are
      older than age nine months.
    explanation: >-
      General pediatric candidacy statement; individual evaluation is required.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Audiologic follow-up
  description: >-
    Follow hearing over time and adapt rehabilitation to documented stability or progression. A DFNA2B-specific
    surveillance interval cannot be assigned from the disputed association.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Document the stability or progression of the hearing loss;
    explanation: >-
      Purpose of sequential audiologic examinations in the general overview.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Avoid repeated loud-noise overexposure
  description: >-
    Counsel people with hearing loss to avoid repeated excessive noise exposure. This is a general precaution
    and does not establish a specific GJB3-environment interaction.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      persons with documented hearing loss should be counseled appropriately and repeated overexposure
      to loud noises should be avoided.
    explanation: >-
      General hearing-loss precaution in the agents-to-avoid section.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
- name: Genetic counseling
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: >-
    Discuss uncertainty, family history, broader testing and reproductive questions. Allele transmission
    and disease recurrence are distinct when pathogenicity is unresolved; do not assign a 50% hearing-loss
    risk from a GJB3 variant alone.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is appropriate to offer genetic counseling (including discussion of the probability of hearing
      loss in offspring and reproductive options) to young adults who have hearing loss.
    explanation: >-
      General counseling recommendation; a disputed GJB3 attribution cannot supply a validated disease
      recurrence risk.
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
clinical_trials:
- name: NCT06133946
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Prospective observational newborn screening cohort, not a therapeutic trial. The registry lists 35,920
    enrolled infants and includes GJB3 c.538C>T among 15 screened variants. Its protocol labels this finding
    as a carrier result; it does not establish GJB3 causality or DFNA2B prevalence. Status checked 2026-09-23;
    registry last update 2023-11-18.
  evidence:
  - reference: clinicaltrials:NCT06133946
    reference_title: "Cohort of Universal Newborn Deafness-gene Screening in Nantong City, China"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This study was based on a concurrent newborn genetic and hearing screening program in Nantong city.
    explanation: >-
      Registry study description establishes observational screening scope, not therapeutic efficacy.
📚

References & Deep Research

References

18
PMID:9843210
Mutations in the gene encoding gap junction protein beta-3 associated with autosomal dominant hearing impairment.
No top-level findings curated for this source.
PMID:11237463
Connexin31-deficiency in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation.
No top-level findings curated for this source.
PMID:21204020
Trafficking abnormality and ER stress underlie functional deficiency of hearing impairment-associated connexin-31 mutants.
No top-level findings curated for this source.
PMID:22617145
Evaluation of the pathogenicity of GJB3 and GJB6 variants associated with nonsyndromic hearing loss.
No top-level findings curated for this source.
PMID:29106878
The relationship between the GJB3 c.538C>T variant and hearing phenotype in the Chinese population.
No top-level findings curated for this source.
PMID:29926981
GJB3/GJB6 screening in GJB2 carriers with idiopathic hearing loss: Is it necessary?
No top-level findings curated for this source.
PMID:37964827
Comparative analysis of allele frequencies of 15 deafness gene variants between hearing-loss and normal populations in Henan, China.
No top-level findings curated for this source.
PMID:19744334
Comprehensive molecular etiology analysis of nonsyndromic hearing impairment from typical areas in China.
No top-level findings curated for this source.
PMID:35677558
A Connexin Gene (GJB3) Mutation in a Chinese Family With Erythrokeratodermia Variabilis, Ichthyosis and Nonsyndromic Hearing Loss: Case Report and Mutations Update.
No top-level findings curated for this source.
PMID:30894701
ClinGen expert clinical validity curation of 164 hearing loss gene-disease pairs.
No top-level findings curated for this source.
PMID:20301388
DFNA2 Nonsyndromic Hearing Loss.
No top-level findings curated for this source.
PMID:18941426
Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus.
No top-level findings curated for this source.
CGGV:assertion_f83e013a-685f-405b-89d6-a8e80aefaf6e-2018-02-27T170000.000Z
GJB3 / nonsyndromic genetic hearing loss (Disputed)
No top-level findings curated for this source.
CGGV:assertion_1d48c959-31d8-44e2-985c-c48921e8f08a-2023-06-01T160000.000Z
GJB3 / erythrokeratodermia variabilis (Definitive)
No top-level findings curated for this source.
PMID:24913888
Mechanism of a novel missense mutation, p.V174M, of the human connexin31 (GJB3) in causing nonsyndromic hearing loss.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1209/?report=reader
DFNA2 Nonsyndromic Hearing Loss - GeneReviews® - NCBI Bookshelf
No top-level findings curated for this source.
clinicaltrials:NCT06133946
Cohort of Universal Newborn Deafness-gene Screening in Nantong City, China
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Review disputed DFNA2B association, molecular evidence and clinical care · 2026-09-23T07:55:02Z · View source

Reviewed the complete DFNA2B entry, prior CREATE record and matching Falcon deep-research scientific report, bibliography, validation appendix and citation sidecar. Confirmed no REVIEW event and no overlapping PR among 123 open PRs at origin/main 2cce588e0a3. This disputed genetic hearing-loss entity is within the narrowed scope; infectious and environmental disorders remain excluded. Named-entity preflight passed for GJB3, MONDO:0012976 and OMIM:612644. Read every originally cited abstract and both ClinGen assertion caches. Checked the live ClinGen GJB3 page: dominant nonsyndromic hearing loss remains Disputed (2018-02-27), while EKV is Definitive (2023-06-01). The EKV assertion used SOP v9, not v11. Independently verified the upstream PMID 12759707 mismatch against PubMed: it is a smoking-prevention editorial and is not used as evidence. No guessed replacement identifier is introduced. Used cached full texts beyond abstract snippets: PMID:19744334 methods/GJB3 results/Table 3; 30894701 ClinGen methods and classification definitions; 18941426 AudioGene methods, validation results and discussion; 35677558 family testing methods, clinical results and mutation discussion; and 37964827 methods, Tables 2/3, case-control results and interpretation. Retrieved the full DFNA2A GeneReviews chapter and the full Genetic Hearing Loss Overview. Read relevant clinical, diagnosis, management, surveillance/noise and counseling sections. The DFNA2A chapter supplies its specific GJB3 differential and founding-family audiogram; the overview supplies phenotype-directed care without establishing GJB3 causality. No GJB3-specific chapter is claimed. Full-text findings change interpretation. The 284-person study sequenced GJB3 in only 188 remaining patients; a normal-hearing V84I homozygote complicates the functional pathogenicity claim. The later paper's nucleotide notation differs; its exact quote is retained and synthesis uses the protein name. The 2023 study found p.Arg180* allele frequencies 0.29% versus 0.30%, not significant, and listed the variant as VUS. Most participants were infants and only 15 sites were screened, limiting adult-onset and other-allele inference. An elevated frequency relative to gnomAD alone is not refutation. In the R98H skin/hearing family, exome sequencing was done in the mother and daughter; the son with hearing loss received limited hotspot sequencing of four genes, not the same broad exclusion of alternatives. AudioGene's 6.3% positive predictive value does not support assigning KCNQ4 from audiogram resemblance. Read the relevant connexin sections of full-text PMID:26074771 and followed the V174M observation to primary PMID:24913888. Added primary evidence for lysosomal accumulation, failed dye transfer and selective interference with Cx26 trafficking while sparing wild-type Cx31 trafficking. The primary remained abstract-only; DOI retrieval also retained an abstract. Re-fetches of 21204020, 22617145 and 29926981 retained abstracts; the 21204020 DOI's OUP PDF returned 403, the 29926981 Wiley PDF returned 403, PMC returned CAPTCHA, EuropePMC XML returned 500 and EuropePMC article retrieval returned 403. These limitations are explicit: no inaccessible full text is represented as read. Unused DOI/review caches are not committed. All cache files were generated with just fetch-reference; none was hand-authored, and the frozen dataset-accessions JSON was not accessed. Removed overstatement in both directions. Disputed is not a linear rank stronger than Limited, and is not equivalent to Refuted. No family history is not incompatible with dominant inheritance, other-gene variants are not automatically confirmed alternative diagnoses, rarity alone does not refute a rare association, and hearing-loss severity is not an audiogram frequency pattern. Removed unsupported FREQUENT phenotype assignments. The ClinGen minimum of at least five probands is dated assertion context, not a current exact total or phenotype refutation. The 2018 GJB2/GJB3 digenic proposal is preserved as a proposed multigenic explanation rather than dismissed based on low yield or promoted to monogenic proof. Separated intracellular trafficking, ER stress and expression-system coupling, plus the V174M-specific Cx26 trafficking effect. R180X ER localization, E183K Golgi-like localization and V174M lysosomal localization are distinct observations. Removed auditory cell-type bindings that had turned expression into evidence of native intercellular coupling. Abnormal coexpression alone does not establish a dominant-negative mechanism. A proposed hypothesis group retains the unestablished bridge to hearing loss. Mouse normal hearing is now modeled against the organismal auditory endpoint rather than a cell-coupling assay. Removed a placental-size readout incorrectly targeted to cochlear coupling. Null-genotype, species and survivor limitations remain; compensation is inferred, and normal null skin does not test every dominant EKV mechanism. Revised proposed experiments so neither one positive knock-in proves dominant negativity nor one negative model retires all human associations. Added general hearing habilitation, implant assessment, audiologic follow-up, counseling and noise precautions with full GeneReviews evidence. Diagnostic interpretation uses broader testing and VUS limits rather than the unvalidated four-item GJB3 checklist. Neither disease-specific treatment response nor a 50% hearing-loss recurrence risk is inferred from the disputed attribution. Added NCT06133946 as an observational newborn screening cohort, not a therapy. ClinicalTrials.gov API checked 2026-09-23: active not recruiting, actual enrollment 35,920; last update 2023-11-18. The protocol includes GJB3 c.538C>T as a carrier result; registry summary evidence describes screening scope without claiming measured prevalence or benefit. Eight-dimension research cross-check: phenotypes adequate after preserving reported bilateral high-frequency loss without unsupported frequency/penetrance; subtypes N/A because no validated separate entities warrant splitting; mechanisms adequate after atomic modeling and variant-specific primary functional evidence, with human causality explicitly unresolved; treatments/trials adequate with phenotype-directed care and the observational registry, no disease-specific Phase II+ treatment surfaced; genetics adequate with variant classes, case-control limits, digenic proposal and family testing limits; diagnostics/biomarkers adequate with audiology, broader genetic testing and uncertainty, no validated GJB3 biomarker inferred; references adequate with relevant full texts, exact titled quotes and primary-source follow-through; overall consumption adequate, addressing central omissions without treating every proposed mechanism as established. General clinical guidance does not validate the disputed molecular diagnosis. Schema, ontology and the first 61 quotations passed; final validation includes the additional counseling and family-methods evidence. Causal/entity links, GeneReviews baseline/tagging and quote-boundary checks passed. Formal author COMMENT, independent review and CI remain separate readiness gates; the history PR link will be added with reviewer follow-up after initial review completes. Final schema, ontology, history and 63/63 quotations passed. Staged hooks normalized YAML layout and generated-cache EOF whitespace; the second staged hook run passed. Independent review follow-up: aligned the remaining AudioGene explanation with its low predictive value; classified the three study-specific result/methods quotations as PRIMARY_RESULT; made broad treatment preferred terms specific to hearing rehabilitation and cochlear implantation. Also bounded the p.Arg180* case-control interpretation, removed unsupported progression from the auditory mechanism name and updated every causal target. Added the PR link after the first independent review completed.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 15 citations 2026-08-28T19:09:06.099808

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Autosomal Dominant Nonsyndromic Hearing Loss 2B (DFNA2B, GJB3-related)
  • MONDO ID: MONDO:0012976 (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on Autosomal Dominant Nonsyndromic Hearing Loss 2B (DFNA2B, GJB3-related) covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Autosomal Dominant Nonsyndromic Hearing Loss 2B (DFNA2B; historically GJB3-related)

Executive summary and evidence qualification

DFNA2B is the historical designation for a rare, autosomal-dominant, nonsyndromic sensorineural hearing-loss phenotype attributed to heterozygous variants in GJB3, which encodes connexin-31 (Cx31). The reported phenotype is usually postlingual, bilateral, progressive, and greatest at high frequencies. A 2023 review places typical recognition in the fourth decade and reports milder loss in females. However, the underlying evidence consists principally of a few small families, and several observations weaken a simple monogenic interpretation: some purported variants occur at appreciable population frequencies, later families show multigenic ambiguity, DFNA2 is genetically heterogeneous, and Gjb3-null mice have normal hearing. Accordingly, a GJB3 result should not establish DFNA2B without rigorous ACMG/AMP classification, phenotype matching, segregation, population-frequency review, and exclusion of better-established hearing-loss genes. (dominguez2012geneticsofhearing pages 5-6, alde2023autosomaldominantnonsyndromic pages 2-3, chen2018gjb3gjb6screeningin pages 2-4, petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4, wingard2015cellularanddeafness pages 8-9)

domain strongest finding evidence type confidence/caveat
Historical gene-disease association DFNA2B was historically attributed to GJB3/connexin 31 based on two small Chinese autosomal-dominant families with high-frequency hearing loss; later reviews note the evidence base is limited and DFNA2 is genetically heterogeneous. (petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4, dominguez2012geneticsofhearing pages 5-6) Human family reports summarized in reviews Low-moderate confidence for a historical association; small pedigrees and later contradictory/heterogeneous DFNA2 data limit certainty.
Core phenotype Reported DFNA2B phenotype is adult-onset, progressive, sloping/high-frequency sensorineural hearing loss; a 2023 review states hearing loss may be milder in females. (alde2023autosomaldominantnonsyndromic pages 2-3, laer1999autosomaldominantnonsyndromic pages 2-3, petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4) Human clinical reviews Moderate confidence for the broad audiophenotype; low confidence for sex effect because it is sparsely documented in secondary summaries.
Functional variant evidence In vitro studies summarized in a mechanistic review report V27M, V43M, and V84I can reach the membrane yet show loss of dye/ion coupling, supporting impaired gap-junction function. (wingard2015cellularanddeafness pages 7-8) In vitro cell-based functional assays (secondary summary) Moderate confidence that these variants can disrupt coupling in cells; direct disease causality in humans remains less certain.
Trafficking mechanism V174M was reported to fail plasma-membrane targeting and instead accumulate in lysosomes; it may also disturb wild-type Cx26 trafficking. (wingard2015cellularanddeafness pages 8-9) In vitro transfected-cell study (secondary summary) Moderate confidence for a trafficking-defect mechanism; relevance to penetrance and phenotype in vivo is unresolved.
Animal-model calibration Gjb3/Cx31-null mice do not show hearing impairment, despite human variant-based disease claims. (wingard2015cellularanddeafness pages 8-9) Mouse knockout model Important caveat / lowers confidence in a simple haploinsufficiency model; dominant-negative, species-specific, or developmental-context mechanisms remain possible.
Cohort/population evidence In a 2018 Chinese cohort of 100 unrelated NSHI families, one putatively relevant p.V84I finding was detected; the paper estimated a very low allele frequency and interpreted the case as digenic/tri-allelic GJB2/GJB3 ambiguity, not clean monogenic proof. (chen2018gjb3gjb6screeningin pages 2-4) Human cohort + segregation/NGS follow-up Low-moderate confidence for contribution of p.V84I; the same study emphasizes ambiguity and possible additive rather than standalone causation.
Current therapy landscape No DFNA2B/GJB3-specific approved therapy was identified; management follows general hereditary hearing-loss care (audiology, hearing aids/cochlear implantation as indicated, counseling). Recent precision-diagnostics literature supports broad NGS-based diagnosis rather than gene-specific treatment. (imizcoz2023nextgenerationsequencingimproves pages 1-2, alde2023autosomaldominantnonsyndromic pages 2-3) Recent clinical review + diagnostic cohort High confidence that no disease-specific therapy currently exists; treatment evidence is extrapolated from broader hereditary hearing-loss practice.
Trial/implementation status The only retrieved GJB3-relevant registered study was NCT06133946, an observational newborn deafness-gene screening cohort, not an intervention trial; it includes a single GJB3 variant among screened targets. (NCT06133946 chunk 1) ClinicalTrials.gov observational study High confidence that current registered activity is screening/epidemiologic rather than therapeutic.

Table: This table summarizes the strongest currently retrievable evidence for the historical DFNA2B–GJB3 association, highlighting where support comes from human families, cell studies, mouse models, and modern screening data. It is useful because the evidence is mixed and requires careful confidence calibration rather than a simple yes/no interpretation.

1. Disease information

Definition

DFNA2B describes inherited nonsyndromic sensorineural hearing loss historically linked to GJB3/Cx31 at chromosome 1p34.3. “Nonsyndromic” means that hearing loss is the principal recognized manifestation; skin disease or peripheral neuropathy should prompt consideration of a distinct, syndromic GJB3-associated phenotype rather than DFNA2B. Historical reports also associated biallelic GJB3 variants with recessive hearing loss, but that is not DFNA2B. (petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4, alde2023autosomaldominantnonsyndromic pages 2-3)

Identifiers and synonyms

  • Requested MONDO identifier: MONDO:0012976. This identifier should be independently verified before database ingestion. The retrieved current Open Targets mapping did not reproduce it; instead, it returned GJB3 against “autosomal dominant nonsyndromic hearing loss 58,” MONDO:0014293, with only one low-scoring evidence item. This discordance is a material ontology-quality warning. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 2B-GJB3)
  • Common names: DFNA2B; deafness, autosomal dominant 2B; autosomal dominant nonsyndromic hearing loss 2B; GJB3-related nonsyndromic hearing loss; connexin-31-related hearing loss.
  • Gene identifiers: GJB3, gap junction protein beta 3; protein Cx31/connexin-31; Ensembl ENSG00000188910. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 2B-GJB3)
  • Cytogenetic location: 1p34.3 in the 2023 review; older literature used the broader 1p33–p35 interval. (alde2023autosomaldominantnonsyndromic pages 2-3, petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4)
  • OMIM/Orphanet: no disease-specific accession was securely recovered in the searched full text; these should be curated directly from the live databases rather than inferred.
  • ICD-10/ICD-11 and MeSH: there is no established genotype-specific clinical code in the retrieved evidence. Use the appropriate bilateral sensorineural/genetic hearing-loss code plus molecular diagnosis; MeSH concepts include Hearing Loss, Sensorineural and Hearing Loss, Hereditary.

The evidence summarized here is aggregated disease-level literature, family studies, experimental models, and a trial registry—not individual EHR-derived data.

2. Etiology

Causal and genetic factors

The proposed primary cause is a germline heterozygous GJB3 variant affecting connexin-31 gap-junction function. The original 1998 report described one missense and one nonsense change in two small Chinese families with autosomal-dominant high-frequency hearing loss (Xia et al., published December 1998, DOI: https://doi.org/10.1038/3845). Historical reviews subsequently assigned this association to DFNA2B. (petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4)

The association is not uniformly secure. DFNA2 also includes the well-established KCNQ4/DFNA2A disorder, and some pedigrees mapping to the region had no causal change in either GJB3 or KCNQ4. In the five-generation UCSF-99 family, sequence changes in both genes occurred in affected and unaffected relatives, arguing against either as causal in that family. These findings demonstrate locus and allelic heterogeneity and make broad use of “DFNA2” as a synonym for GJB3 disease incorrect. (dominguez2012geneticsofhearing pages 5-6)

Risk factors

  • A genuinely pathogenic germline allele and an affected parent are the principal proposed risks; for an established heterozygous autosomal-dominant allele, each child has a theoretical 50% transmission probability.
  • Family history may appear negative because of late onset, reduced/age-dependent penetrance, mild expression, or a de novo event. These are general DFNA principles rather than quantified GJB3-specific observations. (alde2023autosomaldominantnonsyndromic pages 2-3)
  • One 2018 Chinese cohort found GJB3 p.Val84Ile in 1/100 unrelated families with monoallelic GJB2 findings. The authors estimated a 0.5% cohort allele frequency, cited approximately 0.25% among Chinese NSHI cases and 0.0037 in 1000 Genomes, and interpreted the family as possibly digenic/tri-allelic GJB2/GJB3, not clean GJB3 monogenic disease. (chen2018gjb3gjb6screeningin pages 2-4)

Environmental, protective, and gene–environment factors

No DFNA2B-specific toxin, infection, lifestyle factor, protective allele, diet, or validated modifier gene was identified. Noise and ototoxic drugs can independently damage hearing and plausibly add to inherited cochlear vulnerability, but a GJB3-specific interaction has not been demonstrated. General environmental causes—including congenital infection, postnatal infection, ototoxicity, and prematurity—account for a substantial fraction of pediatric hearing loss and must remain in the differential rather than being attributed to GJB3. (imizcoz2023nextgenerationsequencingimproves pages 1-2)

3. Phenotypes

The best-supported phenotype is sensorineural hearing impairment, initially affecting high frequencies, with a sloping audiogram and progressive postlingual course. Older summaries report similar audiograms among affected individuals and suggest that clinically evident loss occurred particularly in older male carriers; the 2023 review describes onset in adulthood, commonly the fourth decade, and milder loss in females. These sex and onset estimates derive from very small historical datasets and should not be treated as precise frequencies. (alde2023autosomaldominantnonsyndromic pages 2-3, laer1999autosomaldominantnonsyndromic pages 2-3)

Suggested HPO annotations are:

  • Sensorineural hearing impairment — HP:0000407
  • High-frequency hearing impairment — HP:0005101
  • Progressive hearing impairment — HP:0001730
  • Postlingual hearing impairment — use the current HPO postlingual-onset hearing-loss term after terminology validation
  • Adult onset — HP:0003581
  • Bilateral hearing impairment — apply the current HPO bilateral-hearing-loss term; bilateral disease is typical for DFNA generally but was not explicitly quantified in the original GJB3 families.

Severity ranges from mild or subclinical to moderate in the most specific GJB3 summaries. Profound congenital loss reported with p.Val84Ile occurred in a family also carrying biallelic GJB2 changes and therefore should not define monogenic DFNA2B. Peripheral neuropathy occurred with an in-frame three-base deletion in a Spanish family and is a syndromic exclusion/red flag, not a core DFNA2B feature. GJB3 variants also cause erythrokeratodermia variabilis; skin findings likewise argue against a nonsyndromic classification. (chen2018gjb3gjb6screeningin pages 2-4, petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4)

No disease-specific quality-of-life instrument has been reported. Expected burdens include impaired speech perception—especially in noise—communication difficulty, educational or occupational limitations, and social/emotional effects. General pediatric evidence indicates that early etiologic diagnosis and intervention improve language, cognitive, emotional, and social development. (imizcoz2023nextgenerationsequencingimproves pages 1-2)

4. Genetic and molecular information

GJB3 encodes a connexin subunit. Six connexins oligomerize into a connexon/hemichannel; connexons in adjacent cells dock to create a gap-junction channel permitting intercellular passage of ions, metabolites, and second messengers. (laer1999autosomaldominantnonsyndromic pages 2-3)

Reported classes include missense, nonsense, and in-frame deletion variants. Functionally studied candidates include:

  • p.Val27Met, p.Val43Met, p.Val84Ile: reached the plasma membrane and formed plaques in cell systems but showed loss of dye and ion permeability.
  • p.Val174Met: failed normal membrane targeting, accumulated in lysosomes, and interfered with wild-type Cx26 trafficking while reportedly not altering wild-type Cx31 trafficking.
  • p.Val84Ile (c.250G>A; rs145751680): computationally damaging and functionally abnormal in vitro, but sufficiently frequent and observed in a multigenic family, making standalone pathogenicity uncertain. (chen2018gjb3gjb6screeningin pages 2-4, wingard2015cellularanddeafness pages 7-8, wingard2015cellularanddeafness pages 8-9)

These assays support loss of channel coupling or abnormal trafficking but do not by themselves prove a variant causes dominant human hearing loss. A dominant-negative or altered heteromeric-channel mechanism is more compatible with normal hearing in Gjb3-null mice than simple haploinsufficiency, although this remains an inference. (wingard2015cellularanddeafness pages 8-9)

All reported inherited disease variants are germline; no somatic origin is relevant. No reproducible GJB3-specific modifier gene, epigenetic signature, pathogenic copy-number alteration, translocation, inversion, or other chromosomal abnormality was identified. GJB2 is a plausible interacting connexin in selected reports, but evidence for digenic causation is limited. (chen2018gjb3gjb6screeningin pages 2-4)

5. Environmental information

No infectious agent causes DFNA2B, and the disorder is not transmissible. Smoking, alcohol, exercise, diet, pollution, radiation, or occupational exposures have not been shown to determine GJB3 penetrance. Clinically, ordinary hearing-conservation measures remain prudent because noise and ototoxic exposure can independently worsen auditory function. Infection, prematurity, and ototoxicity should be evaluated as alternative or additional etiologies, especially when onset or progression does not fit the family phenotype. (imizcoz2023nextgenerationsequencingimproves pages 1-2)

6. Mechanism and pathophysiology

Proposed causal chain

  1. A GJB3 sequence variant alters Cx31 folding, trafficking, connexon assembly, docking, gating, or molecular permeability.
  2. Gap-junctional transfer of ions and signaling/metabolic molecules among inner-ear nonsensory/supporting cells—or possibly auditory/peripheral nerve cells—is reduced or qualitatively changed.
  3. Cochlear homeostasis and cellular coupling become less robust.
  4. High-frequency auditory function is affected first, producing a sloping audiogram; dysfunction then progresses to lower frequencies.

Steps 1–2 have cell-based support for selected variants; steps 3–4 remain a biologically plausible but incompletely demonstrated bridge in GJB3 disease. Historical chicken data localized Cx31 to cells lining the scala media but not hair cells, while rat inner-ear expression was also reported. Human cochlear localization remains poorly defined. (laer1999autosomaldominantnonsyndromic pages 2-3, petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4, wingard2015cellularanddeafness pages 8-9)

The traditional “potassium recycling” account should not be stated as established for Cx31. Connexin channels also transmit metabolites, ATP/IP3-related signals, and calcium-wave information, and modern connexin work has challenged potassium-recycling failure as a universal explanation. No GJB3-specific immune, inflammatory, metabolic, lipidomic, metabolomic, or oxidative-stress signature has been established. (wingard2015cellularanddeafness pages 7-8, wingard2015cellularanddeafness pages 8-9)

Suggested annotations include:

  • GO: gap junction assembly; gap-junction-mediated intercellular transport; cell–cell signaling; ion transmembrane transport; cellular homeostasis.
  • GO cellular components: gap junction; connexin complex; plasma membrane; lysosome for trafficking-defective p.Val174Met.
  • Candidate cell types: cochlear supporting/nonsensory epithelial cell; auditory-neuron/Schwann-cell populations only where demonstrated. Use exact CL identifiers after ontology validation.

No DFNA2B-specific single-cell, spatial-transcriptomic, multi-omic, CRISPR-screen, proteomic, metabolomic, or lipidomic study was identified through 2024.

7. Anatomical structures affected

The primary organ is the inner ear/cochlea, within the auditory system. Candidate sites include the scala-media-lining epithelium and auditory nerve, but direct human pathology is lacking. Hair cells themselves were excluded from Cx31 expression in the cited chicken work, so direct hair-cell expression should not be asserted. (laer1999autosomaldominantnonsyndromic pages 2-3)

Suggested anatomical terms include UBERON: inner ear; cochlea; scala media; organ of Corti; stria vascularis; spiral ligament; cochlear nerve. These are candidate knowledge-base annotations and not all are proven GJB3-expression sites. The clinical pattern is expected to be bilateral; no consistent asymmetry, vestibular-organ disease, or secondary-organ involvement is established for nonsyndromic DFNA2B. Peripheral nerve or skin involvement changes the classification to a syndromic GJB3 phenotype. (petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4)

8. Temporal development

The disease is chronic and generally insidious. Current secondary synthesis describes onset in the fourth decade, while older DFNA literature broadly places autosomal-dominant nonsyndromic loss in the second or third decade. Initial high-frequency impairment may be mild or subclinical and progressively involves more frequencies. There are no validated clinical stages, quantified annual threshold shifts, remission pattern, or spontaneous recovery. (alde2023autosomaldominantnonsyndromic pages 2-3, laer1999autosomaldominantnonsyndromic pages 2-3)

The practical intervention window begins before communication disability becomes substantial: identify at-risk relatives, establish baseline audiometry, and monitor serially. Childhood-onset or congenital profound hearing loss should trigger aggressive reassessment for other genes or acquired causes rather than automatic attribution to classic DFNA2B.

9. Inheritance and population

The historical model is autosomal dominant, affecting both sexes, with 50% transmission risk from a heterozygous parent. Expression appears variable and may be age- and sex-dependent; neither penetrance nor the male:female ratio has been quantified. Anticipation, germline mosaicism, founder effects, consanguinity effects, and carrier frequency have not been established. (alde2023autosomaldominantnonsyndromic pages 2-3, laer1999autosomaldominantnonsyndromic pages 2-3)

No reliable prevalence or incidence estimate exists for DFNA2B. The original evidence involved two small Chinese families; a Spanish family had hearing loss plus neuropathy. A later Chinese series found only one p.Val84Ile-positive family among 100 selected cases and did not establish monogenic GJB3 causation. Therefore, ethnicity-specific enrichment and geographic prevalence cannot currently be inferred. (chen2018gjb3gjb6screeningin pages 2-4, petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4)

For context only, disabling hearing loss affects over 5% of the global population, and hearing loss occurs in approximately 1–2 per 1,000 European newborns; these are not DFNA2B-specific estimates. (imizcoz2023nextgenerationsequencingimproves pages 1-2)

10. Diagnostics

Diagnosis should combine:

  1. History: age at onset, progression, noise/ototoxic exposure, infections, and a three-generation pedigree.
  2. Examination: otologic assessment plus targeted examination for skin disease and peripheral neuropathy.
  3. Audiology: pure-tone thresholds, speech testing, tympanometry, otoacoustic emissions, and ABR/ASSR where age or phenotype warrants.
  4. Molecular testing: a comprehensive hereditary-hearing-loss NGS panel with SNV/indel and CNV detection is preferable to GJB3-only testing. Confirm candidate variants orthogonally and perform segregation analysis.
  5. Interpretation: ACMG/AMP classification, population-frequency review, phenotype concordance, and analysis of competing genes—especially KCNQ4, GJB2, GJB6, TECTA, WFS1, ACTG1, POU4F3, MYO6, and EYA4.

A 2023 Spanish study of a 171-nuclear/8-mitochondrial-gene panel produced a diagnosis in 52/155 (34%) cases; 45/52 diagnoses were recessive, 6/52 dominant, 1/52 mitochondrial, and 3/52 involved pathogenic CNVs. Its abstract states that NGS panels “reduce the clinical diagnostic odyssey in hearing loss.” Published 22 September 2023; DOI: https://doi.org/10.3389/fgene.2023.1264899. This supports broad genomic testing, not the validity of any particular GJB3 allele. (imizcoz2023nextgenerationsequencingimproves pages 1-2)

WES or WGS is appropriate after a nondiagnostic panel or for complex/atypical families. CMA, karyotype, FISH, mitochondrial testing, and repeat-expansion testing are not routine DFNA2B tests unless another clinical indication exists. RNA-seq and other omics remain research tools.

Differential diagnoses include KCNQ4-related DFNA2A, other dominant nonsyndromic hearing losses, age-related and noise-induced hearing loss, ototoxicity, congenital infection, auditory neuropathy, and GJB3-associated neuropathy or erythrokeratodermia. Cascade testing is appropriate only after a familial variant has been convincingly classified.

11. Outcome and prognosis

DFNA2B is not known to shorten life expectancy or cause disease-specific mortality. Morbidity is auditory and communication-related. Hearing loss is generally permanent and progressive rather than episodic or remitting. Prognosis depends on baseline thresholds, rate of progression, speech discrimination, age, environmental exposures, and timely rehabilitation; no validated GJB3 molecular prognostic biomarker exists. (alde2023autosomaldominantnonsyndromic pages 2-3, laer1999autosomaldominantnonsyndromic pages 2-3)

Untreated loss can impair communication, education, work, and psychosocial well-being. Hearing technology can improve function but does not correct the molecular defect. Disease-specific hearing-aid or cochlear-implant response rates have not been published.

12. Treatment

There is no approved GJB3-directed drug, gene therapy, RNA therapy, cell therapy, or genome-editing treatment. Standard management is phenotype-directed:

  • serial audiologic monitoring;
  • properly fitted hearing aids for aidable loss;
  • assistive listening devices and communication accommodations;
  • auditory rehabilitation and speech/language support;
  • cochlear-implant evaluation for severe-to-profound loss with inadequate aided speech recognition;
  • treatment of unrelated middle-ear disease and avoidance of unnecessary ototoxic exposure.

Suggested NCIT concepts include Hearing Aid, Cochlear Implantation, Audiologic Evaluation, Speech Therapy, Rehabilitation Therapy, and Genetic Counseling; exact codes should be validated against the current NCIt release.

ClinicalTrials.gov NCT06133946 (CODES) is not a therapy trial. It is an observational Nantong newborn cohort enrolling 35,920 participants, screening 15 variants in GJB2, SLC26A4, MT-RNR1, and GJB3 (c.538C>T), with ABR/ASSR and developmental follow-up. Recruitment ran January 2016–December 2020; the record is active but not recruiting, with estimated completion in December 2028. (NCT06133946 chunk 1)

13. Prevention

Primary prevention of a germline disorder is not available. Risk reduction consists of genetic counseling and reproductive options after confirmation of a pathogenic familial allele: prenatal diagnosis or preimplantation genetic testing may be considered according to patient values and local regulations. Because GJB3 pathogenicity is frequently uncertain, reproductive testing should not be based on a VUS.

Secondary prevention includes cascade testing, baseline audiometry, periodic surveillance, newborn hearing screening, and prompt rehabilitation. Tertiary prevention includes hearing conservation, avoidance of unnecessary ototoxic drugs, communication support, and timely hearing aids or implantation. Vaccination does not prevent DFNA2B but routine immunization can reduce selected acquired infectious causes of hearing loss.

14. Other species and natural disease

Orthologous Gjb3 exists in mouse and other vertebrates. No naturally occurring veterinary disorder convincingly equivalent to human DFNA2B was identified, and there is no zoonotic or cross-species transmission. Conserved connexin architecture makes vertebrates useful for comparative channel biology, but species differences are important: complete Cx31 deficiency in mice causes transient placental dysmorphogenesis without hearing impairment. (wingard2015cellularanddeafness pages 8-9)

Suggested taxonomy annotations include Homo sapiens (NCBI Taxon 9606), Mus musculus (10090), Rattus norvegicus (10116), and Gallus gallus (9031) for the expression evidence. No relevant VBO breed term is applicable.

15. Model organisms and experimental systems

Mouse

The Gjb3/Cx31 knockout is the most important calibration model. It does not reproduce human hearing loss, although placental abnormalities occur transiently. Consequently, it argues against uncomplicated loss-of-function/haploinsufficiency as the universal human mechanism and limits its use as a faithful DFNA2B efficacy model. It remains useful for studying redundancy among connexins and extra-auditory biology. (wingard2015cellularanddeafness pages 8-9)

Cellular systems

HEK293 and HeLa transfection systems have assessed localization, plaque formation, dye transfer, ionic coupling, and interactions with Cx26. They demonstrate functional abnormalities for selected variants, including defective permeability and lysosomal retention, but overexpression, noncochlear cellular context, and uncertain connexin stoichiometry limit translation. (chen2018gjb3gjb6screeningin pages 2-4, wingard2015cellularanddeafness pages 7-8, wingard2015cellularanddeafness pages 8-9)

No validated GJB3 patient-derived iPSC cochlear organoid, humanized knock-in mouse, zebrafish disease model, or CRISPR therapeutic model was identified. High-priority future work includes patient-derived cochlear-like cells, variant-specific knock-in models, allele-specific expression studies, direct human inner-ear localization, and large pedigree-based segregation with modern population databases.

Recent-development assessment (2023–2024)

The principal recent advance is diagnostic rather than GJB3-specific: broad NGS/CNV pipelines are increasingly implemented for genetically heterogeneous hearing loss, with a 34% yield in one 2023 Spanish cohort. The 2023 DFNA review still lists GJB3/DFNA2B and describes fourth-decade, progressive, sloping hearing loss, but it does not resolve the sparse primary evidence or normal-hearing knockout contradiction. No 2023–2024 disease-specific natural-history cohort, validated prevalence study, therapy trial, single-cell atlas analysis, or variant-reclassification study was retrieved. (alde2023autosomaldominantnonsyndromic pages 2-3, imizcoz2023nextgenerationsequencingimproves pages 1-2, wingard2015cellularanddeafness pages 8-9)

Knowledge-base recommendation

Represent DFNA2B as a historical/provisional GJB3-associated dominant nonsyndromic hearing-loss entity with limited evidence, not as an unequivocally established diagnosis for every rare GJB3 variant. Store variant-level assertions separately, record the evidence type, and flag p.Val84Ile and other incompletely segregating alleles for expert review. The highest-value missing data are modern ClinGen-style gene–disease curation, current ClinVar/gnomAD variant review, larger pedigrees, human inner-ear expression data, and variant-specific in-vivo models.

References

  1. (dominguez2012geneticsofhearing pages 5-6): L. M. Dominguez and K. Dodson. Genetics of hearing loss: focus on dfna2. The Application of Clinical Genetics, 5:97-104, Oct 2012. URL: https://doi.org/10.2147/tacg.s35525, doi:10.2147/tacg.s35525. This article has 24 citations.

  2. (alde2023autosomaldominantnonsyndromic pages 2-3): Mirko Aldè, Giovanna Cantarella, Diego Zanetti, Lorenzo Pignataro, Ignazio La Mantia, Luigi Maiolino, Salvatore Ferlito, Paola Di Mauro, Salvatore Cocuzza, Jérôme René Lechien, Giannicola Iannella, Francois Simon, and Antonino Maniaci. Autosomal dominant non-syndromic hearing loss (dfna): a comprehensive narrative review. Biomedicines, 11:1616, Jun 2023. URL: https://doi.org/10.3390/biomedicines11061616, doi:10.3390/biomedicines11061616. This article has 65 citations.

  3. (chen2018gjb3gjb6screeningin pages 2-4): Kaitian Chen, Xuan Wu, Ling Zong, and Hongyan Jiang. Gjb3/gjb6 screening in gjb2 carriers with idiopathic hearing loss: is it necessary? Journal of Clinical Laboratory Analysis, Jun 2018. URL: https://doi.org/10.1002/jcla.22592, doi:10.1002/jcla.22592. This article has 12 citations and is from a peer-reviewed journal.

  4. (petersen2002non‐syndromicautosomal‐dominantdeafness pages 2-4): MB Petersen. Non‐syndromic autosomal‐dominant deafness. Clinical Genetics, 62:1-13, Jul 2002. URL: https://doi.org/10.1034/j.1399-0004.2002.620101.x, doi:10.1034/j.1399-0004.2002.620101.x. This article has 117 citations and is from a peer-reviewed journal.

  5. (wingard2015cellularanddeafness pages 8-9): Jeffrey C. Wingard and Hong-Bo Zhao. Cellular and deafness mechanisms underlying connexin mutation-induced hearing loss – a common hereditary deafness. Frontiers in Cellular Neuroscience, May 2015. URL: https://doi.org/10.3389/fncel.2015.00202, doi:10.3389/fncel.2015.00202. This article has 199 citations.

  6. (laer1999autosomaldominantnonsyndromic pages 2-3): Lut Van Laer, Wyman T. McGuirt, Tao Yang, Richard J.H. Smith, and Guy Van Camp. Autosomal dominant nonsyndromic hearing impairment. American journal of medical genetics, 89 3:167-74, Sep 1999. URL: https://doi.org/10.1002/(sici)1096-8628(19990924)89:3<167::aid-ajmg7>3.0.co;2-v, doi:10.1002/(sici)1096-8628(19990924)89:3<167::aid-ajmg7>3.0.co;2-v. This article has 52 citations.

  7. (wingard2015cellularanddeafness pages 7-8): Jeffrey C. Wingard and Hong-Bo Zhao. Cellular and deafness mechanisms underlying connexin mutation-induced hearing loss – a common hereditary deafness. Frontiers in Cellular Neuroscience, May 2015. URL: https://doi.org/10.3389/fncel.2015.00202, doi:10.3389/fncel.2015.00202. This article has 199 citations.

  8. (imizcoz2023nextgenerationsequencingimproves pages 1-2): T. Imizcoz, C. Prieto-Matos, R. Manrique-Huarte, D. Calavia, A. Huarte, P. C. Pruneda, G. R. Ordoñez, E. Cañada-Higueras, A. Patiño-García, G. Alkorta-Aranburu, M. M. Rodríguez, Kelvin Yuen-Kwong, Chan, Sze Wing Cheng, and S. Taiber. Next-generation sequencing improves precision medicine in hearing loss. Frontiers in Genetics, Sep 2023. URL: https://doi.org/10.3389/fgene.2023.1264899, doi:10.3389/fgene.2023.1264899. This article has 15 citations and is from a peer-reviewed journal.

  9. (NCT06133946 chunk 1): Gang Qin, MD, PhD. Cohort Of DEafness-gene Screening. Affiliated Hospital of Nantong University. 2016. ClinicalTrials.gov Identifier: NCT06133946

  10. (OpenTargets Search: autosomal dominant nonsyndromic hearing loss 2B-GJB3): Open Targets Query (autosomal dominant nonsyndromic hearing loss 2B-GJB3, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 9
Resolved 7
Unresolved (possible confabulation) 2
Unverifiable 0
References weighed for topical relevance 7
On topic 3
Off topic 0

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • DOI:10.1002/(sici)1096-8628(19990924)89:3 (2 mentions) - Identifier did not resolve to a record
  • DOI:10.1002/(sici (1 mention) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 6
Resolved 6
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 1
Terms named correctly 0
Terms named as a different term 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0012976 (2 mentions) - the report calls it "if available"; MONDO calls it autosomal dominant nonsyndromic hearing loss 2B